US20110270226A1 - Balloon catheter devices with sheath covering - Google Patents
Balloon catheter devices with sheath covering Download PDFInfo
- Publication number
- US20110270226A1 US20110270226A1 US13/179,054 US201113179054A US2011270226A1 US 20110270226 A1 US20110270226 A1 US 20110270226A1 US 201113179054 A US201113179054 A US 201113179054A US 2011270226 A1 US2011270226 A1 US 2011270226A1
- Authority
- US
- United States
- Prior art keywords
- sheath
- balloon
- therapeutic agent
- weakened portions
- medical device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
- A61M25/1029—Production methods of the balloon members, e.g. blow-moulding, extruding, deposition or by wrapping a plurality of layers of balloon material around a mandril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M2025/0056—Catheters; Hollow probes characterised by structural features provided with an antibacterial agent, e.g. by coating, residing in the polymer matrix or releasing an agent out of a reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
- A61M25/1029—Production methods of the balloon members, e.g. blow-moulding, extruding, deposition or by wrapping a plurality of layers of balloon material around a mandril
- A61M2025/1031—Surface processing of balloon members, e.g. coating or deposition; Mounting additional parts onto the balloon member's surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M25/0045—Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2009/00—Layered products
- B29L2009/005—Layered products coated
Definitions
- the present invention relates to medical devices, more particularly, to catheter devices.
- Balloon catheters having drug coatings may be used to treat diseased portions of blood vessels.
- the balloon is inserted through a peripheral blood vessel and then guided via a catheter through the vascular system to the target intravascular site.
- the flow of blood may wash away some of the drug coating.
- the control of the timing, location, and/or duration of the drug release can be an issue. Therefore, there is a need for improved catheter-based devices for drug delivery to an intravascular site.
- the present invention provides a medical device comprising: a catheter; a balloon mounted on the catheter; one or more sheaths disposed around the balloon, wherein the one or more sheaths are slidable over the balloon; and a therapeutic agent disposed between the surface of the balloon and the one or more sheaths.
- the therapeutic agent may be formulated to include a pharmaceutically-acceptable lubricant material.
- the present invention provides a medical device comprising: a catheter; a balloon mounted on the catheter; a sheath disposed around the balloon, wherein the sheath has a weakened portion, and wherein the sheath is disrupted at the weakened portion when the balloon is expanded; and a therapeutic agent disposed between the surface of the balloon and the sheath.
- the present invention provides a medical device comprising: a catheter; a balloon mounted on the catheter; a sheath disposed around the balloon, wherein the sheath comprises nanofibers; and a therapeutic agent retained on the medical device by the sheath.
- the present invention provides a medical device comprising: a catheter; a balloon mounted on the catheter; a sheath disposed around the balloon, wherein the sheath comprises a body and a plurality of reservoirs that are in communication with the external surface of the body of the sheath, wherein the reservoirs are longitudinally-extending channels within the body of the sheath; and a therapeutic agent contained in the reservoirs.
- the present invention provides a method for making a medical device, comprising: providing a balloon; disposing over the surface of the balloon, a layer of therapeutic agent; embossing a pattern onto the layer of therapeutic agent; and disposing a sheath over the layer of therapeutic agent.
- FIG. 1 shows a cross-section side view of a portion of a sheath according to an embodiment. It is to be noted that certain features in these drawings have been exaggerated to more clearly show details thereof. For example, in FIG. 1 , the size of the fibers and therapeutic agents are exaggerated relative to the thickness of the sheath.
- FIG. 2 shows a magnified side view of a surface of a sheath according to another embodiment.
- FIG. 3 shows a magnified side view of a surface of a sheath according to another embodiment.
- FIGS. 4A and 4B show a catheter device according to another embodiment.
- FIG. 4A shows the catheter device with the balloon in a deflated stated.
- FIG. 4B shows the catheter device with the balloon inflated.
- FIGS. 5A-5C show a catheter device according to another embodiment.
- FIG. 5A shows the catheter device with the balloon in a deflated state.
- FIG. 5B shows a transverse cross-section view of the balloon taken at arrow A in FIG. 5A .
- FIG. 5C shows a transverse cross-section view of the balloon taken at arrow A in FIG. 5A with the balloon inflated.
- FIGS. 6A-6D show a catheter device according to another embodiment.
- FIGS. 6A and 6B (transverse cross-section view) show the catheter device with the balloon in a deflated state.
- FIGS. 6C and 6D (transverse cross-section view) show the catheter device with the balloon inflated.
- FIGS. 7A-7D show a catheter device according to another embodiment.
- FIGS. 7A and 7B (enlarged view of the elastomeric mesh) show the catheter device with the balloon in a deflated state.
- FIGS. 7C and 7D (enlarged view of the elastomeric mesh) show the catheter device with the balloon inflated.
- FIGS. 8A and 8B show side views of a catheter device according to another embodiment.
- FIGS. 9A and 9B show side views of a catheter device according to another embodiment.
- FIGS. 10A and 10B show side views of a catheter device according to another embodiment.
- FIGS. 11A and 11B show side views of a catheter device according to another embodiment.
- FIGS. 12A-12C show transverse cross-sections of a portion of a balloon according to an embodiment.
- FIGS. 13A-13C show images of a nanofiber sheath wrapped around a balloon in its folded configuration.
- FIGS. 14A and 14B show images of a nanofiber sheath wrapped around a balloon in its inflated configuration.
- FIGS. 15A-15C show the wall of a balloon according to yet another embodiment.
- FIG. 15A shows a cross-section perspective view of a fragment of the balloon wall.
- FIG. 15B shows a cross-sectional side view of the balloon wall shown in FIG. 15A .
- FIG. 15C shows the balloon wall of FIG. 15B after the caps have been actuated to open.
- Catheter devices of the present invention use an expandable balloon for delivering a therapeutic agent to a target site in the body.
- the balloon is designed to be insertable in the body via a catheter.
- the therapeutic agent can be associated with the balloon in any of various ways, as further described below. Any of various mechanisms conventionally used for the delivery, actuation, or expansion (e.g., by inflation) of balloon catheter devices may be used in the present invention.
- the balloon catheter may be designed similar to those that have been known in the art, including but not limited to angioplasty catheters, stent delivery catheters, inflation catheters, and/or perfusion catheters.
- the catheter devices of the present invention may be used in conjunction with other drug delivery devices, such as stents.
- one or more sheaths are disposed around the balloon.
- the sheath may be made of various types of materials, and in some cases, the sheath may be formed of a permeable or semi-permeable material to allow the passage of the therapeutic agent through the sheath.
- the sheath may be made of expanded polytetrafluoro-ethylene (ePTFE), which can be made by expanding PTFE tubing under controlled conditions during the manufacturing process. This expansion process alters the physical properties of the PTFE tubing such that microscopic pores are created in the tube.
- ePTFE expanded polytetrafluoro-ethylene
- the sheath can also be made from various other types of polymeric materials, such as polyolefin copolymers, fluoropolymers, noncompliant polyethylene terephthalate (PET), polyimide, nylon, polyethylene, PEBAX, or the like.
- the sheath may have varying degrees of compliance depending upon the type of balloon being used and the particular application.
- the sheath may be attached to the surface of the balloon (e.g., at one or more points or continuously) or the sheath may be free of any attachments to the surface of the balloon (e.g., the sheath is “free-floating” over the balloon surface).
- a therapeutic agent can be disposed over the sheath, within the sheath, or between the balloon and the sheath.
- the therapeutic agent can be associated with the sheath in various ways.
- a sheath 100 has a fibrous structure (e.g., a fibrous mat-like structure) containing a network of fibers 102 , and therapeutic agent 104 is dispersed within the network of fibers 102 .
- the surface 110 of a sheath is rough-textured and therapeutic agent 114 is dispersed in the interstices 112 of the rough-textured surface.
- a surface 120 of a sheath has numerous pili 122 (e.g., hair-like projections) extending from surface 120 , and therapeutic agent 124 is dispersed between pili 122 .
- a catheter device 80 comprises a balloon 84 mounted on an elongate shaft 82 (note that balloon 84 may have a smaller unexpanded profile relative to the shaft 82 than that illustrated in FIG. 4A ).
- Balloon 84 is coated with a therapeutic agent 18 which is formulated to include a pharmaceutically-acceptable lubricant material.
- the pharmaceutically-acceptable lubricant material can either be incorporated into a matrix comprising the therapeutic agent or the therapeutic agent can be directly disposed on the outer surface of balloon 84 and the lubricant can be placed over the therapeutic agent as a top coat.
- the proximal half of balloon 84 is covered by a proximally located sheath 85 and the distal half of balloon 84 is covered by a distally located sheath 86 .
- the edges of proximal sheath 85 and distal sheath 86 meet or overlap near the middle, for example, of balloon 84 so that therapeutic agent 18 on balloon 84 is enclosed within the sheaths.
- the edges of proximal sheath 85 and distal sheath 86 can meet or overlap at another portion of balloon 84 .
- the edges of the proximal sheath 85 and the distal sheath 86 may be separated, in which case it may be desirable to have the therapeutic agent only on those portions of the balloon covered by the sheaths.
- balloon 84 is inserted into the body via a catheter, with the balloon in an unexpanded condition as shown in FIG. 4A . Because therapeutic agent 18 is covered by sheaths 85 and 86 , therapeutic agent 18 is protected while balloon 84 is being guided to the target site. At the target site, as shown in FIG. 4B , balloon 84 is inflated. Expansion of balloon 84 causes sheaths 85 and 86 to slip across the surface of balloon 84 and be pulled proximally and distally, respectively, thus exposing therapeutic agent 18 for release at the target site. In an alternate embodiment, therapeutic agent 18 is applied to the inner surface of sheaths 85 and 86 so that therapeutic agent 18 is smeared onto the surface of balloon 84 as the sheaths retract.
- the sheath comprises a body and a plurality of reservoirs for containing a therapeutic agent.
- the reservoirs can be, for example, longitudinally-extending channels within the body of the sheath. As the balloon is expanded within the sheath, the expanding balloon applies pressure against the reservoirs to push the therapeutic agent out of the reservoirs. In some cases, two or more of the reservoirs may be in communication with each other.
- a catheter device 40 comprises a balloon 48 mounted on an elongate shaft 43 (note that balloon 48 may have a smaller uninflated profile relative to shaft 43 than what is depicted in FIG. 5A ).
- Balloon 48 is enclosed in a sheath 42 that is shaped and dimensioned to allow balloon 48 to expand within sheath 42 .
- Sheath 42 has a plurality of longitudinally extending channels 44 which contain a therapeutic agent 18 . Each channel 44 is in communication with a plurality of pores 47 on the external surface of sheath 42 via openings 46 . As shown in FIG.
- FIG. 5B shows a space between channels 44 and balloon 48 which is for illustration purposes only. This space is not necessary and channels 44 may be in contact with un-inflated balloon 48 .
- the sheath 42 may be fitted snugly around the un-inflated balloon 48 .
- catheter device 40 is inserted into the body via a catheter.
- balloon 48 is inflated, causing it to press against channels 44 .
- Internal pressure in channels 44 causes therapeutic agent 18 to be forced through openings 46 and out of pores 47 of sheath 42 .
- the sheath has a non-linear compliance curve.
- Balloons having high compliance at smaller inflation diameters and low compliance at larger inflation diameters are described in U.S. Pat. No. 5,348,538 (Wang et al.), which is incorporated by reference herein.
- Such balloons can be made using the shrunken balloon technique described in Wang et al., which is incorporated by reference herein.
- a high compliance balloon will undergo a relatively large increase in diameter in response to an increase in inflation pressure
- a low compliance balloon will undergo a relatively small increase in diameter in response to an increase in inflation pressure.
- a sheath of the present invention can be made in the same or similar manner, such that it has high compliance at smaller expansion diameters and low compliance at larger expansion diameters.
- a sheath can be formed of ePTFE having a porous cell structure. As the sheath expands in diameter with inflation of the balloon, the size of the pores in the sheath increase, making it more permeable to the therapeutic agent.
- a catheter device 150 comprises a balloon 156 mounted on an elongate shaft 152 .
- Balloon 156 has an inflation chamber 155 .
- Balloon 156 is covered with a sheath 154 formed of ePTFE having a porous cell structure.
- Sheath 154 has a non-linear compliance curve, such that it has high compliance at smaller expansion diameters and low compliance at larger expansion diameters.
- Disposed between the outer surface of balloon 156 and sheath 154 is a therapeutic agent 18 .
- balloon 156 is inserted into the body via a catheter. Because therapeutic agent 18 is covered by sheath 154 , therapeutic agent 18 is protected while balloon 156 is being guided to the target site. At the target site, as shown in FIGS. 6C and 6D , balloon 156 is inflated. With the inflation of balloon 156 , sheath 154 also expands. Initially, sheath 154 expands with relatively high compliance. Also, as sheath 154 expands, the pores in sheath 154 increase in size, allowing the release of therapeutic agent 18 through sheath 154 . With further inflation of balloon 156 and expansion of sheath 154 , sheath 154 becomes less compliant as it reaches its predetermined maximum diameter.
- the sheath e.g., of ePTFE
- This deflation or shrinking process can allow subsequent over-expansion of the sheath or ePTFE layer to create a larger cell size to allow for burst release of the therapeutic agent.
- the shrinking process facilitates the use of higher inflation pressures.
- the sheath may be elastomeric and expands upon inflation of the balloon.
- the elastomeric sheath may be an elastomeric mesh. With expansion, the widened spaces of the mesh allow for the release of the therapeutic agent.
- the elastomeric mesh may comprise a biodegradable material (e.g., polyglycolic acid, polylactic acid, polyanhydride, etc.).
- the medical device may further include a biodegradable stent (e.g., made of a biodegradable polymer or bioresorbable metal, such as magnesium) disposed over the balloon, with the biodegradable stent being covered by the elastomeric mesh.
- a catheter device 160 comprises a balloon 166 mounted on an elongate shaft 162 .
- Balloon 166 has an inflation chamber 165 .
- Balloon 166 is covered with an expandable sheath 164 formed of an elastomeric mesh 168 having interstices 169 (see FIG. 7B ).
- Disposed between the outer surface of balloon 166 and sheath 164 is a therapeutic agent 18 .
- intersticial openings 169 are sufficiently small such that therapeutic agent 18 is trapped by elastomeric mesh 168 of sheath 164 (e.g., less than 25 ⁇ m, or less than 10 ⁇ m in size, or another suitable size depending upon the particular application).
- balloon 166 is inserted into the body via a catheter. Because therapeutic agent 18 is covered by sheath 164 , therapeutic agent 18 is protected while balloon 166 is being guided to the target site. At the target site, as shown in FIG. 7C , balloon 166 is inflated. With the inflation of balloon 166 , sheath 164 also expands. Expansion of sheath 164 causes the widening of intersticial openings 169 (see FIG. 7D ), which allows for the release of therapeutic agent 18 .
- sheath 164 may further have numerous pili as shown in FIG. 3 .
- therapeutic agent 18 that passes through the wall of sheath 164 may then be “smeared” onto the inner wall of the blood vessel when the balloon is retracted through the blood vessel.
- the therapeutic agent may be formulated with a biocompatible adhesive substance.
- the sheath is designed to tear, break, or otherwise become disrupted at one or more points when the sheath expands as a result of balloon inflation.
- the sheath is provided with one or more weakened portions where the tearing, breaking, or disruption occurs.
- the weakened portions are areas where the sheath has a different structure or composition than other areas of the sheath, wherein the different structure or composition at the weakened portions cause the area to be structurally weaker than the other areas of the sheath.
- the weakened portions may be slots, slits, grooves, or perforations in the sheath.
- the weakened portions may have any of various orientations or configurations relative to the balloon, including radial, longitudinal, grid-like, or random.
- the tearing, breaking, or disruption of the sheath allows the release of the therapeutic agent.
- the weakened portions may be areas where the sheath is attached to the balloon such that disruption of the sheath preferentially occurs at the attachment points.
- Such attachments can be made by, for example, spot welding of the sheath to the balloon.
- a catheter device 200 comprises a balloon 204 mounted on an elongate shaft 202 .
- Balloon 204 is coated with a therapeutic agent 18 (not shown in FIG. 8A ).
- Balloon 204 is enclosed within a sheath 206 such that therapeutic agent 18 is covered by sheath 206 .
- Sheath 206 has a plurality of longitudinally extending perforation lines 208 , along which sheath 206 is designed to tear.
- balloon 204 (enclosed within sheath 206 ) is inserted into the body via a catheter. Because therapeutic agent 18 is covered by sheath 206 , therapeutic agent 18 is protected while balloon 204 is being guided to the target site. At the target site, as shown in FIG. 8B , balloon 204 is inflated, causing sheath 206 to also expand. Expansion of sheath 206 causes tearing of sheath 206 along perforation lines 208 to form tears 209 . Tears 209 expose therapeutic agent 18 on the surface of balloon 204 such that therapeutic agent 18 is released.
- a catheter device 210 comprises a balloon 214 (not shown in FIG. 9A ) mounted on an elongate shaft 212 .
- Balloon 214 is coated with a therapeutic agent 18 (not shown in FIG. 9A ).
- Balloon 214 is enclosed within a sheath 216 such that therapeutic agent 18 is covered by sheath 216 .
- Sheath 216 has a plurality of radially extending perforation lines 218 , along which sheath 216 is designed to tear.
- balloon 214 enclosed within sheath 216 is inserted into the body via a catheter. Because therapeutic agent 18 is covered by sheath 216 , therapeutic agent 18 is protected while balloon 214 is being guided to the target site.
- balloon 214 is inflated, causing sheath 216 to also expand. Expansion of sheath 216 causes tearing of sheath 216 along perforation lines 218 to form tears 219 . Tears 219 expose therapeutic agent 18 on the surface of balloon 214 such that therapeutic agent 18 is released.
- a catheter device 220 comprises a balloon 224 (not shown in FIG. 10A ) mounted on an elongate shaft 222 .
- Balloon 224 is coated with a therapeutic agent 18 (not shown in FIG. 10A ).
- Balloon 224 is enclosed within a sheath 226 such that therapeutic agent 18 is covered by sheath 226 .
- sheath 226 has a circumferentially extending perforation line 228 , along which sheath 226 is designed to tear.
- balloon 224 enclosed within sheath 226 is inserted into the body via a catheter. Because therapeutic agent 18 is covered by sheath 226 , therapeutic agent 18 is protected while balloon 224 is being guided to the target site.
- balloon 224 is inflated, causing sheath 226 to also expand. Expansion of sheath 226 causes tearing of sheath 226 at perforation line 228 (creating sheath edges 229 ) as proximal portion 226 ′ and distal portion 226 ′′ of sheath 226 are pulled in opposite directions. This tearing of sheath 226 exposes therapeutic agent 18 on the surface of balloon 224 such that therapeutic agent 18 is released.
- a catheter device 230 comprises a balloon 234 (not shown in FIG. 11A ) mounted on an elongate shaft 232 .
- Balloon 234 is coated with a therapeutic agent 18 (not shown in FIG. 11A ).
- Balloon 234 is enclosed within a sheath 236 such that therapeutic agent 18 is covered by sheath 236 .
- Sheath 236 has a plurality of perforation lines 238 oriented in a grid-like pattern, along which sheath 236 is designed to tear.
- the size of at least some of the individual grid units may be in the micron range (e.g., less than 100 ⁇ m, or less than 10 ⁇ m) such that the fragments would not cause an embolism.
- balloon 234 enclosed within sheath 236 is inserted into the body via a catheter. Because therapeutic agent 18 is covered by sheath 236 , therapeutic agent 18 is protected while balloon 234 is being guided to the target site.
- balloon 234 is inflated, causing sheath 236 to also expand. Expansion of sheath 236 causes tearing of sheath 236 at perforation lines 238 , which results in the fragmentation of sheath 236 into fragments 239 .
- the size of fragments 239 may be in the micron range (e.g., less than 100 ⁇ m, or less than 10 ⁇ m). This fragmentation of sheath 236 exposes therapeutic agent 18 on the surface of the balloon 234 such that therapeutic agent 18 is released.
- a catheter device comprises a balloon having a surface 240 .
- a layer of therapeutic agent 18 is deposited onto surface 240 of the balloon.
- the layer of therapeutic agent 18 is then embossed with a pattern (e.g., by stamping) to create ridges 242 and depressions 244 in the layer of therapeutic agent 18 .
- the layer of therapeutic agent 18 can be formulated in any suitable way to allow this type of patterning (e.g., by including a binder material, such as polyvinylpyrrolidone).
- a sheath is provided by depositing a film 246 (representing a sheath) of brittle material, such as low molecular weight poly(lactic-co-glycolic acid) (PLGA) or low molecular weight poly(lactic acid) (PLA), onto the patterned layer of therapeutic agent 18 .
- Film 246 may also be made of a non-polymeric material, such as salts of moderate to high molecular weight.
- Film 246 that is located over ridges 242 is thinner (at regions 247 ) relative to film 246 that is located over depressions 244 (at regions 249 ).
- a pattern of thin regions 247 in film 246 allows film 246 to fragment upon expansion of the balloon.
- thin regions 247 may be attached to the surface 240 of the balloon (e.g., by spot welding), which can enhance fragmentation of film 246 .
- the sheath comprises nanofibers.
- the nanofibers are formed of any suitable polymer material, including polymers that are elastic.
- the nanofibers may have diameters (thickness) that are less than 1 ⁇ m (e.g., in the range of 200 nm-1 ⁇ m).
- the nanofibers may comprise biodegradable polymers, such as poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid) (PLA), or uncured poly(ethylene oxide) (PEO).
- the nanofibers may also comprise non-biodegradable polymers, such as poly(styrene-isobutylene-styrene) (SIBS) block copolymers, polyamides (e.g., nylon), polyesters, polyethylene, polyurethane, or carbon fiber.
- SIBS poly(styrene-isobutylene-styrene)
- the nanofibers may be disposed over the balloon in any of various ways.
- the nanofibers are wound circumferentially around the body of the balloon.
- the nanofibers may be wound around the balloon loosely or under elastic tension. Where the nanofibers are wound around the balloon under elastic tension, the elastic tension may restrain the balloon in its unexpanded or folded configuration.
- FIGS. 13A-13C show PLGA nanofibers wrapped circumferentially around a balloon in its folded configuration.
- FIG. 13A shows a side view of the balloon;
- FIG. 13B shows a close-up view of a portion of the balloon, with the nanofibers being more visible;
- FIG. 13C shows a scanning-electron micrograph of the nanofiber sheath showing the individual nanofibers.
- FIGS. 14A and 14B show PLGA nanofibers wrapped circumferentially around a balloon in its inflated configuration.
- FIG. 14A shows a side view of the balloon; and
- FIG. 14B shows a close-up view of a portion of the balloon, with the nanofibers being more visible.
- the nanofibers are deposited as a tangled mat on the balloon.
- additional nanofibers may be wound circumferentially around the tangled mat of nanofibers (e.g., to encase the tangled mat of nanofibers).
- the nanofibers may be disposed over the balloon with the balloon in any suitable configuration (e.g., inflated or uninflated, folded or unfolded).
- the nanofibers may be disposed over the entire balloon or over only a portion of the balloon (e.g., between the cones).
- the therapeutic agent may be associated with the nanofiber sheath in any of various ways.
- the therapeutic agent may be provided in any suitable form, including as a liquid, a gel, or a solid.
- the therapeutic agent is contained between the nanofiber sheath and the balloon (i.e., the sheath covers over the therapeutic agent).
- the therapeutic agent can be deposited on the balloon and the nanofibers are spun (e.g., by electro-spinning) over the therapeutic agent to encase and protect it.
- the sheath comprises a tangled mat of nanofibers
- the therapeutic agent may be dispersed within the network of nanofibers. In some cases, the therapeutic agent may be dispersed in the spaces between the nanofibers.
- the therapeutic agent may constitute part of the composition of the nanofibers and be released upon degradation of the nanofibers.
- the therapeutic agent may be contained in the nanofiber solution and spun with the nanofibers.
- the therapeutic agent may be released through any of various mechanisms.
- the therapeutic agent may be released through gaps or openings between the nanofibers.
- the therapeutic agent may be squeezed through such gaps or openings.
- stretching of the nanofibers as the balloon expands causes thinning of the nanofibers. This thinning of the nanofibers increases the spacing between the nanofibers, providing openings for the release of the therapeutic agent.
- the nanofibers may also serve other functions.
- elastic nanofibers may serve to control the folding or re-folding of the balloon or control the shape or dimensions of the expanded balloon.
- the balloon includes a micro-electromechanical system (MEMS) for drug delivery.
- MEMS micro-electromechanical system
- Various types of drug delivery systems using MEMS are known in the art, such as microfluidic devices that incorporate micropumps, valves, or flow channels; microfabricated porous membranes for drug encapsulation; microparticles for carrying drugs; and the microchip devices for drug delivery described in U.S. Pat. No. 6,656,162 (Santini et al.).
- a catheter device comprises a balloon having a substrate layer 52 on the surface of the balloon wall 50 .
- Substrate layer 52 has a plurality of micro-sized reservoirs 54 which contain a therapeutic agent 18 .
- Reservoirs 54 are formed using any of various microfabrication techniques, including lithographic etching, molding, or micromachining (e.g., laser drilling).
- substrate layer 52 is made of a material which can be shaped by microfabrication techniques, including for example, ceramics, metal oxides, semiconductor materials, and polymers.
- Reservoirs 54 have openings 55 through which therapeutic agent 18 may be released.
- reservoirs 54 are covered by reservoir caps 56 formed of a shape memory material.
- shape memory material e.g., shape memory polymers and shape memory alloys (e.g., nitinol).
- the balloon is inserted into the body via a catheter.
- the balloon is inflated and reservoir caps 56 are actuated to open (e.g., by bending), allowing therapeutic agent 18 contained in reservoirs 54 to be released.
- Reservoir caps 56 may be actuated in any of various ways, including temperature change or application of an electric current.
- the configuration of the balloon and the sheath can be controlled such as to allow release of the therapeutic agent only at the desired time.
- the device may be designed such that a certain pressure within the balloon is required for the sheath to release the therapeutic agent (e.g., by retracting, fracturing, fragmenting, opening pores, etc.). In this way, the therapeutic agent can be held in the folds while the device is delivered through the blood vessel to the target site. Then, at the target site, the balloon is inflated to the pressure and/or diameter at which the sheaths are designed to release the therapeutic agent.
- the therapeutic agent release can be controlled such that it is released only if the balloon is in contact with or in close proximity to the vessel wall. This helps to prevent loss of the therapeutic agent during catheter placement and balloon inflation. Also, because deflation of the balloon can, in some instances, stop or substantially reduce therapeutic agent release, certain embodiments of the invention can control the duration of release after the initial release of therapeutic agent.
- Medical devices of the present invention may also include a vascular stent mounted on the balloon.
- the vascular stent may be any of those known in the art, including those with or without coatings that elute a therapeutic agent.
- the stent may also be biostable, bioerodible, or biodegradable.
- the balloons of the present invention may also be coated with a low-molecular weight carbohydrate, such as mannitol.
- the carbohydrate may be a separate coating or be blended with the therapeutic agent.
- the balloons of the present invention may also be coated with a radiocontrast agent (ionic or non-ionic), such as iopromide.
- the contrast agent may be a separate coating or be blended with the therapeutic agent.
- the therapeutic agent used in the present invention may be any pharmaceutically-acceptable agent such as a drug, a non-genetic therapeutic agent, a biomolecule, a small molecule, or cells.
- Example drugs include anti-proliferative agents or anti-restenosis agents such as paclitaxel, sirolimus (rapamycin), tacrolimus, everolimus, and zotarolimus.
- non-genetic therapeutic agents include anti-thrombogenic agents such heparin, heparin derivatives, prostaglandin (including micellar prostaglandin E1), urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone); anti-proliferative agents such as enoxaparin, angiopeptin, sirolimus (rapamycin), tacrolimus, everolimus, zotarolimus, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid; anti-inflammatory agents such as dexamethasone, rosiglitazone, prednisolone, corticosterone, budesonide, estrogen, estrodiol, sulfasalazine, acetylsalicylic acid, mycophenolic acid, and mesalamine; anti-neoplastic/anti-proliferative/anti-mitotic agents such
- biomolecules include peptides, polypeptides and proteins; oligonucleotides; nucleic acids such as double or single stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), and ribozymes; genes; carbohydrates; angiogenic factors including growth factors; cell cycle inhibitors; and anti-restenosis agents.
- Nucleic acids may be incorporated into delivery systems such as, for example, vectors (including viral vectors), plasmids or liposomes.
- Non-limiting examples of proteins include serca-2 protein, monocyte chemoattractant proteins (MCP-1) and bone morphogenic proteins (“BMP's”), such as, for example, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (VGR-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15.
- BMP's are any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, and BMP-7. These BMPs can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules.
- molecules capable of inducing an upstream or downstream effect of a BMP can be provided.
- Such molecules include any of the “hedgehog” proteins, or the DNA's encoding them.
- genes include survival genes that protect against cell death, such as anti-apoptotic Bcl-2 family factors and Akt kinase; serca 2 gene; and combinations thereof.
- Non-limiting examples of angiogenic factors include acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factors ⁇ and ⁇ , platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor ⁇ , hepatocyte growth factor, and insulin-like growth factor.
- a non-limiting example of a cell cycle inhibitor is a cathespin D (CD) inhibitor.
- Non-limiting examples of anti-restenosis agents include p15, p16, p18, p19, p21, p27, p53, p57, Rb, nFkB and E2F decoys, thymidine kinase and combinations thereof and other agents useful for interfering with cell proliferation.
- Exemplary small molecules include hormones, nucleotides, amino acids, sugars, and lipids and compounds have a molecular weight of less than 100 kD.
- Exemplary cells include stem cells, progenitor cells, endothelial cells, adult cardiomyocytes, and smooth muscle cells.
- Cells can be of human origin (autologous or allogenic) or from an animal source (xenogenic), or genetically engineered.
- Non-limiting examples of cells include side population (SP) cells, lineage negative (Lin ⁇ ) cells including Lin ⁇ CD34 ⁇ , Lin ⁇ CD34 + , Lin ⁇ cKit + , mesenchymal stem cells including mesenchymal stem cells with 5-aza, cord blood cells, cardiac or other tissue derived stem cells, whole bone marrow, bone marrow mononuclear cells, endothelial progenitor cells, skeletal myoblasts or satellite cells, muscle derived cells, go cells, endothelial cells, adult cardiomyocytes, fibroblasts, smooth muscle cells, adult cardiac fibroblasts +5-aza, genetically modified cells, tissue engineered grafts, MyoD scar fibroblasts, pac
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Manufacturing & Machinery (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Catheter devices having an expandable balloon for delivering a therapeutic agent to a body site. In one aspect, one or more sheaths are disposed around the balloon with the therapeutic agent being disposed within the sheath, being disposed over the sheath, being contained in the space between the sheath and the balloon, or being otherwise associated with the sheath. In another aspect, the balloon includes a micro-electromechanical system (MEMS) for drug delivery.
Description
- This application is a divisional of application Ser. No. 12/399,386 filed Mar. 6, 2009, which claims the benefit of provisional application Ser. No. 61/034,328 filed Mar. 6, 2008, both of which are incorporated by reference herein.
- The present invention relates to medical devices, more particularly, to catheter devices.
- Catheters are used in a wide variety of minimally-invasive or percutaneous medical procedures. Balloon catheters having drug coatings may be used to treat diseased portions of blood vessels. Typically, the balloon is inserted through a peripheral blood vessel and then guided via a catheter through the vascular system to the target intravascular site. However, as the balloon travels through the vascular system, the flow of blood may wash away some of the drug coating. In addition, the control of the timing, location, and/or duration of the drug release can be an issue. Therefore, there is a need for improved catheter-based devices for drug delivery to an intravascular site.
- In one embodiment, the present invention provides a medical device comprising: a catheter; a balloon mounted on the catheter; one or more sheaths disposed around the balloon, wherein the one or more sheaths are slidable over the balloon; and a therapeutic agent disposed between the surface of the balloon and the one or more sheaths. The therapeutic agent may be formulated to include a pharmaceutically-acceptable lubricant material.
- In another embodiment, the present invention provides a medical device comprising: a catheter; a balloon mounted on the catheter; a sheath disposed around the balloon, wherein the sheath has a weakened portion, and wherein the sheath is disrupted at the weakened portion when the balloon is expanded; and a therapeutic agent disposed between the surface of the balloon and the sheath.
- In another embodiment, the present invention provides a medical device comprising: a catheter; a balloon mounted on the catheter; a sheath disposed around the balloon, wherein the sheath comprises nanofibers; and a therapeutic agent retained on the medical device by the sheath.
- In another embodiment, the present invention provides a medical device comprising: a catheter; a balloon mounted on the catheter; a sheath disposed around the balloon, wherein the sheath comprises a body and a plurality of reservoirs that are in communication with the external surface of the body of the sheath, wherein the reservoirs are longitudinally-extending channels within the body of the sheath; and a therapeutic agent contained in the reservoirs.
- In another embodiment, the present invention provides a method for making a medical device, comprising: providing a balloon; disposing over the surface of the balloon, a layer of therapeutic agent; embossing a pattern onto the layer of therapeutic agent; and disposing a sheath over the layer of therapeutic agent.
-
FIG. 1 shows a cross-section side view of a portion of a sheath according to an embodiment. It is to be noted that certain features in these drawings have been exaggerated to more clearly show details thereof. For example, inFIG. 1 , the size of the fibers and therapeutic agents are exaggerated relative to the thickness of the sheath. -
FIG. 2 shows a magnified side view of a surface of a sheath according to another embodiment. -
FIG. 3 shows a magnified side view of a surface of a sheath according to another embodiment. -
FIGS. 4A and 4B show a catheter device according to another embodiment.FIG. 4A shows the catheter device with the balloon in a deflated stated.FIG. 4B shows the catheter device with the balloon inflated. -
FIGS. 5A-5C show a catheter device according to another embodiment.FIG. 5A shows the catheter device with the balloon in a deflated state.FIG. 5B shows a transverse cross-section view of the balloon taken at arrow A inFIG. 5A .FIG. 5C shows a transverse cross-section view of the balloon taken at arrow A inFIG. 5A with the balloon inflated. -
FIGS. 6A-6D show a catheter device according to another embodiment.FIGS. 6A and 6B (transverse cross-section view) show the catheter device with the balloon in a deflated state.FIGS. 6C and 6D (transverse cross-section view) show the catheter device with the balloon inflated. -
FIGS. 7A-7D show a catheter device according to another embodiment.FIGS. 7A and 7B (enlarged view of the elastomeric mesh) show the catheter device with the balloon in a deflated state.FIGS. 7C and 7D (enlarged view of the elastomeric mesh) show the catheter device with the balloon inflated. -
FIGS. 8A and 8B show side views of a catheter device according to another embodiment. -
FIGS. 9A and 9B show side views of a catheter device according to another embodiment. -
FIGS. 10A and 10B show side views of a catheter device according to another embodiment. -
FIGS. 11A and 11B show side views of a catheter device according to another embodiment. -
FIGS. 12A-12C show transverse cross-sections of a portion of a balloon according to an embodiment. -
FIGS. 13A-13C show images of a nanofiber sheath wrapped around a balloon in its folded configuration. -
FIGS. 14A and 14B show images of a nanofiber sheath wrapped around a balloon in its inflated configuration. -
FIGS. 15A-15C show the wall of a balloon according to yet another embodiment.FIG. 15A shows a cross-section perspective view of a fragment of the balloon wall.FIG. 15B shows a cross-sectional side view of the balloon wall shown inFIG. 15A .FIG. 15C shows the balloon wall ofFIG. 15B after the caps have been actuated to open. - It is to be noted that certain features in these drawings have been exaggerated to more clearly show details thereof. For example, the diameter of an uninflated balloon relative to the thickness of the catheter shaft may be smaller than what is depicted in the drawings.
- Catheter devices of the present invention use an expandable balloon for delivering a therapeutic agent to a target site in the body. The balloon is designed to be insertable in the body via a catheter. The therapeutic agent can be associated with the balloon in any of various ways, as further described below. Any of various mechanisms conventionally used for the delivery, actuation, or expansion (e.g., by inflation) of balloon catheter devices may be used in the present invention. The balloon catheter may be designed similar to those that have been known in the art, including but not limited to angioplasty catheters, stent delivery catheters, inflation catheters, and/or perfusion catheters. The catheter devices of the present invention may be used in conjunction with other drug delivery devices, such as stents.
- In one aspect of the present invention, one or more sheaths are disposed around the balloon. The sheath may be made of various types of materials, and in some cases, the sheath may be formed of a permeable or semi-permeable material to allow the passage of the therapeutic agent through the sheath. For example, the sheath may be made of expanded polytetrafluoro-ethylene (ePTFE), which can be made by expanding PTFE tubing under controlled conditions during the manufacturing process. This expansion process alters the physical properties of the PTFE tubing such that microscopic pores are created in the tube. The sheath can also be made from various other types of polymeric materials, such as polyolefin copolymers, fluoropolymers, noncompliant polyethylene terephthalate (PET), polyimide, nylon, polyethylene, PEBAX, or the like. The sheath may have varying degrees of compliance depending upon the type of balloon being used and the particular application. The sheath may be attached to the surface of the balloon (e.g., at one or more points or continuously) or the sheath may be free of any attachments to the surface of the balloon (e.g., the sheath is “free-floating” over the balloon surface).
- Further, a therapeutic agent can be disposed over the sheath, within the sheath, or between the balloon and the sheath. The therapeutic agent can be associated with the sheath in various ways. For example, referring to
FIG. 1 , asheath 100 has a fibrous structure (e.g., a fibrous mat-like structure) containing a network offibers 102, andtherapeutic agent 104 is dispersed within the network offibers 102. In another example, referring to the magnified side view shown inFIG. 2 , thesurface 110 of a sheath is rough-textured andtherapeutic agent 114 is dispersed in theinterstices 112 of the rough-textured surface. In another example, referring to the magnified side view shown inFIG. 3 , asurface 120 of a sheath has numerous pili 122 (e.g., hair-like projections) extending fromsurface 120, andtherapeutic agent 124 is dispersed betweenpili 122. - In certain embodiments, the sheath is designed to retract away from the balloon as the balloon is expanded. For example, referring to the embodiment shown in
FIGS. 4A and 4B , acatheter device 80 comprises aballoon 84 mounted on an elongate shaft 82 (note thatballoon 84 may have a smaller unexpanded profile relative to theshaft 82 than that illustrated inFIG. 4A ).Balloon 84 is coated with atherapeutic agent 18 which is formulated to include a pharmaceutically-acceptable lubricant material. The pharmaceutically-acceptable lubricant material can either be incorporated into a matrix comprising the therapeutic agent or the therapeutic agent can be directly disposed on the outer surface ofballoon 84 and the lubricant can be placed over the therapeutic agent as a top coat. The proximal half ofballoon 84 is covered by a proximally locatedsheath 85 and the distal half ofballoon 84 is covered by a distally locatedsheath 86. The edges ofproximal sheath 85 anddistal sheath 86 meet or overlap near the middle, for example, ofballoon 84 so thattherapeutic agent 18 onballoon 84 is enclosed within the sheaths. Of course, the edges ofproximal sheath 85 anddistal sheath 86 can meet or overlap at another portion ofballoon 84. In addition, as an alternate embodiment, the edges of theproximal sheath 85 and thedistal sheath 86 may be separated, in which case it may be desirable to have the therapeutic agent only on those portions of the balloon covered by the sheaths. - In operation,
balloon 84 is inserted into the body via a catheter, with the balloon in an unexpanded condition as shown inFIG. 4A . Becausetherapeutic agent 18 is covered bysheaths therapeutic agent 18 is protected whileballoon 84 is being guided to the target site. At the target site, as shown inFIG. 4B ,balloon 84 is inflated. Expansion ofballoon 84 causes sheaths 85 and 86 to slip across the surface ofballoon 84 and be pulled proximally and distally, respectively, thus exposingtherapeutic agent 18 for release at the target site. In an alternate embodiment,therapeutic agent 18 is applied to the inner surface ofsheaths therapeutic agent 18 is smeared onto the surface ofballoon 84 as the sheaths retract. - In certain embodiments, the sheath comprises a body and a plurality of reservoirs for containing a therapeutic agent. The reservoirs can be, for example, longitudinally-extending channels within the body of the sheath. As the balloon is expanded within the sheath, the expanding balloon applies pressure against the reservoirs to push the therapeutic agent out of the reservoirs. In some cases, two or more of the reservoirs may be in communication with each other.
- For example, referring to the embodiment shown in
FIGS. 5A-5C , acatheter device 40 comprises aballoon 48 mounted on an elongate shaft 43 (note thatballoon 48 may have a smaller uninflated profile relative toshaft 43 than what is depicted inFIG. 5A ).Balloon 48 is enclosed in asheath 42 that is shaped and dimensioned to allowballoon 48 to expand withinsheath 42.Sheath 42 has a plurality of longitudinally extendingchannels 44 which contain atherapeutic agent 18. Eachchannel 44 is in communication with a plurality ofpores 47 on the external surface ofsheath 42 viaopenings 46. As shown inFIG. 5B , when balloon 48 (shown with inflation chamber 49) is in a deflated state,channels 44 are in a relaxed condition.FIG. 5B shows a space betweenchannels 44 andballoon 48 which is for illustration purposes only. This space is not necessary andchannels 44 may be in contact withun-inflated balloon 48. Thesheath 42 may be fitted snugly around theun-inflated balloon 48. - In operation,
catheter device 40 is inserted into the body via a catheter. At the target site, as shown inFIG. 5C ,balloon 48 is inflated, causing it to press againstchannels 44. Internal pressure inchannels 44 causestherapeutic agent 18 to be forced throughopenings 46 and out ofpores 47 ofsheath 42. - In certain embodiments, the sheath has a non-linear compliance curve. Balloons having high compliance at smaller inflation diameters and low compliance at larger inflation diameters (i.e., a non-linear or hybrid compliance curve) are described in U.S. Pat. No. 5,348,538 (Wang et al.), which is incorporated by reference herein. Such balloons can be made using the shrunken balloon technique described in Wang et al., which is incorporated by reference herein. In general, a high compliance balloon will undergo a relatively large increase in diameter in response to an increase in inflation pressure, whereas a low compliance balloon will undergo a relatively small increase in diameter in response to an increase in inflation pressure. As such, a sheath of the present invention can be made in the same or similar manner, such that it has high compliance at smaller expansion diameters and low compliance at larger expansion diameters. In some cases, such a sheath can be formed of ePTFE having a porous cell structure. As the sheath expands in diameter with inflation of the balloon, the size of the pores in the sheath increase, making it more permeable to the therapeutic agent.
- For example, referring to the embodiment shown in
FIGS. 6A-6D , acatheter device 150 comprises aballoon 156 mounted on anelongate shaft 152.Balloon 156 has aninflation chamber 155.Balloon 156 is covered with asheath 154 formed of ePTFE having a porous cell structure.Sheath 154 has a non-linear compliance curve, such that it has high compliance at smaller expansion diameters and low compliance at larger expansion diameters. Disposed between the outer surface ofballoon 156 andsheath 154 is atherapeutic agent 18. - In operation,
balloon 156 is inserted into the body via a catheter. Becausetherapeutic agent 18 is covered bysheath 154,therapeutic agent 18 is protected whileballoon 156 is being guided to the target site. At the target site, as shown inFIGS. 6C and 6D ,balloon 156 is inflated. With the inflation ofballoon 156,sheath 154 also expands. Initially,sheath 154 expands with relatively high compliance. Also, assheath 154 expands, the pores insheath 154 increase in size, allowing the release oftherapeutic agent 18 throughsheath 154. With further inflation ofballoon 156 and expansion ofsheath 154,sheath 154 becomes less compliant as it reaches its predetermined maximum diameter. - In certain embodiments, it may be desirable to apply the sheath (e.g., of ePTFE) over a balloon that has been inflated and then deflated. This deflation or shrinking process can allow subsequent over-expansion of the sheath or ePTFE layer to create a larger cell size to allow for burst release of the therapeutic agent. When a relatively non-compliant balloon is used, the shrinking process facilitates the use of higher inflation pressures.
- In certain embodiments, the sheath may be elastomeric and expands upon inflation of the balloon. In some cases, the elastomeric sheath may be an elastomeric mesh. With expansion, the widened spaces of the mesh allow for the release of the therapeutic agent. In some cases, the elastomeric mesh may comprise a biodegradable material (e.g., polyglycolic acid, polylactic acid, polyanhydride, etc.). In some cases, the medical device may further include a biodegradable stent (e.g., made of a biodegradable polymer or bioresorbable metal, such as magnesium) disposed over the balloon, with the biodegradable stent being covered by the elastomeric mesh.
- For example, referring to the embodiment shown in
FIGS. 7A-7D , acatheter device 160 comprises aballoon 166 mounted on anelongate shaft 162.Balloon 166 has aninflation chamber 165.Balloon 166 is covered with anexpandable sheath 164 formed of anelastomeric mesh 168 having interstices 169 (seeFIG. 7B ). Disposed between the outer surface ofballoon 166 andsheath 164 is atherapeutic agent 18. Withballoon 166 in a deflated state andsheath 154 unexpanded,intersticial openings 169 are sufficiently small such thattherapeutic agent 18 is trapped byelastomeric mesh 168 of sheath 164 (e.g., less than 25 μm, or less than 10 μm in size, or another suitable size depending upon the particular application). - In operation,
balloon 166 is inserted into the body via a catheter. Becausetherapeutic agent 18 is covered bysheath 164,therapeutic agent 18 is protected whileballoon 166 is being guided to the target site. At the target site, as shown inFIG. 7C ,balloon 166 is inflated. With the inflation ofballoon 166,sheath 164 also expands. Expansion ofsheath 164 causes the widening of intersticial openings 169 (seeFIG. 7D ), which allows for the release oftherapeutic agent 18. - In some cases,
sheath 164 may further have numerous pili as shown inFIG. 3 . In such cases,therapeutic agent 18 that passes through the wall ofsheath 164 may then be “smeared” onto the inner wall of the blood vessel when the balloon is retracted through the blood vessel. In such cases, the therapeutic agent may be formulated with a biocompatible adhesive substance. - In certain embodiments, the sheath is designed to tear, break, or otherwise become disrupted at one or more points when the sheath expands as a result of balloon inflation. The sheath is provided with one or more weakened portions where the tearing, breaking, or disruption occurs. The weakened portions are areas where the sheath has a different structure or composition than other areas of the sheath, wherein the different structure or composition at the weakened portions cause the area to be structurally weaker than the other areas of the sheath. For example, the weakened portions may be slots, slits, grooves, or perforations in the sheath. The weakened portions may have any of various orientations or configurations relative to the balloon, including radial, longitudinal, grid-like, or random. The tearing, breaking, or disruption of the sheath allows the release of the therapeutic agent. In some cases, the weakened portions may be areas where the sheath is attached to the balloon such that disruption of the sheath preferentially occurs at the attachment points. Such attachments can be made by, for example, spot welding of the sheath to the balloon.
- Referring to the embodiment shown in
FIGS. 8A and 8B , acatheter device 200 comprises aballoon 204 mounted on anelongate shaft 202.Balloon 204 is coated with a therapeutic agent 18 (not shown inFIG. 8A ).Balloon 204 is enclosed within asheath 206 such thattherapeutic agent 18 is covered bysheath 206.Sheath 206 has a plurality of longitudinally extendingperforation lines 208, along whichsheath 206 is designed to tear. - In operation, balloon 204 (enclosed within sheath 206) is inserted into the body via a catheter. Because
therapeutic agent 18 is covered bysheath 206,therapeutic agent 18 is protected whileballoon 204 is being guided to the target site. At the target site, as shown inFIG. 8B ,balloon 204 is inflated, causingsheath 206 to also expand. Expansion ofsheath 206 causes tearing ofsheath 206 alongperforation lines 208 to form tears 209.Tears 209 exposetherapeutic agent 18 on the surface ofballoon 204 such thattherapeutic agent 18 is released. - Referring to the embodiment shown in
FIGS. 9A and 9B , acatheter device 210 comprises a balloon 214 (not shown inFIG. 9A ) mounted on anelongate shaft 212.Balloon 214 is coated with a therapeutic agent 18 (not shown inFIG. 9A ).Balloon 214 is enclosed within asheath 216 such thattherapeutic agent 18 is covered bysheath 216.Sheath 216 has a plurality of radially extendingperforation lines 218, along whichsheath 216 is designed to tear. - In operation,
balloon 214 enclosed withinsheath 216 is inserted into the body via a catheter. Becausetherapeutic agent 18 is covered bysheath 216,therapeutic agent 18 is protected whileballoon 214 is being guided to the target site. At the target site, as shown in FIG. 10B,balloon 214 is inflated, causingsheath 216 to also expand. Expansion ofsheath 216 causes tearing ofsheath 216 alongperforation lines 218 to form tears 219.Tears 219 exposetherapeutic agent 18 on the surface ofballoon 214 such thattherapeutic agent 18 is released. - Referring to the embodiment shown in
FIGS. 10A and 10B , acatheter device 220 comprises a balloon 224 (not shown inFIG. 10A ) mounted on anelongate shaft 222.Balloon 224 is coated with a therapeutic agent 18 (not shown inFIG. 10A ).Balloon 224 is enclosed within asheath 226 such thattherapeutic agent 18 is covered bysheath 226. At its midportion,sheath 226 has a circumferentially extendingperforation line 228, along whichsheath 226 is designed to tear. - In operation,
balloon 224 enclosed withinsheath 226 is inserted into the body via a catheter. Becausetherapeutic agent 18 is covered bysheath 226,therapeutic agent 18 is protected whileballoon 224 is being guided to the target site. At the target site, as shown inFIG. 10B ,balloon 224 is inflated, causingsheath 226 to also expand. Expansion ofsheath 226 causes tearing ofsheath 226 at perforation line 228 (creating sheath edges 229) asproximal portion 226′ anddistal portion 226″ ofsheath 226 are pulled in opposite directions. This tearing ofsheath 226 exposestherapeutic agent 18 on the surface ofballoon 224 such thattherapeutic agent 18 is released. - Referring to the embodiment shown in
FIGS. 11A and 11B , acatheter device 230 comprises a balloon 234 (not shown inFIG. 11A ) mounted on anelongate shaft 232.Balloon 234 is coated with a therapeutic agent 18 (not shown inFIG. 11A ).Balloon 234 is enclosed within asheath 236 such thattherapeutic agent 18 is covered bysheath 236.Sheath 236 has a plurality ofperforation lines 238 oriented in a grid-like pattern, along whichsheath 236 is designed to tear. The size of at least some of the individual grid units may be in the micron range (e.g., less than 100 μm, or less than 10 μm) such that the fragments would not cause an embolism. - In operation,
balloon 234 enclosed withinsheath 236 is inserted into the body via a catheter. Becausetherapeutic agent 18 is covered bysheath 236,therapeutic agent 18 is protected whileballoon 234 is being guided to the target site. At the target site, as shown inFIG. 11B ,balloon 234 is inflated, causingsheath 236 to also expand. Expansion ofsheath 236 causes tearing ofsheath 236 atperforation lines 238, which results in the fragmentation ofsheath 236 intofragments 239. The size offragments 239 may be in the micron range (e.g., less than 100 μm, or less than 10 μm). This fragmentation ofsheath 236 exposestherapeutic agent 18 on the surface of theballoon 234 such thattherapeutic agent 18 is released. - Referring to the embodiment shown in
FIGS. 12A-12C , a catheter device comprises a balloon having asurface 240. As shown inFIG. 12A , a layer oftherapeutic agent 18 is deposited ontosurface 240 of the balloon. As shown inFIG. 12B , the layer oftherapeutic agent 18 is then embossed with a pattern (e.g., by stamping) to createridges 242 anddepressions 244 in the layer oftherapeutic agent 18. The layer oftherapeutic agent 18 can be formulated in any suitable way to allow this type of patterning (e.g., by including a binder material, such as polyvinylpyrrolidone). - As shown in
FIG. 12C , a sheath is provided by depositing a film 246 (representing a sheath) of brittle material, such as low molecular weight poly(lactic-co-glycolic acid) (PLGA) or low molecular weight poly(lactic acid) (PLA), onto the patterned layer oftherapeutic agent 18.Film 246 may also be made of a non-polymeric material, such as salts of moderate to high molecular weight.Film 246 that is located overridges 242 is thinner (at regions 247) relative to film 246 that is located over depressions 244 (at regions 249). Thus, a pattern ofthin regions 247 infilm 246 allowsfilm 246 to fragment upon expansion of the balloon. In some cases,thin regions 247 may be attached to thesurface 240 of the balloon (e.g., by spot welding), which can enhance fragmentation offilm 246. - In certain embodiments, the sheath comprises nanofibers. The nanofibers are formed of any suitable polymer material, including polymers that are elastic. The nanofibers may have diameters (thickness) that are less than 1 μm (e.g., in the range of 200 nm-1 μm). The nanofibers may comprise biodegradable polymers, such as poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid) (PLA), or uncured poly(ethylene oxide) (PEO). The nanofibers may also comprise non-biodegradable polymers, such as poly(styrene-isobutylene-styrene) (SIBS) block copolymers, polyamides (e.g., nylon), polyesters, polyethylene, polyurethane, or carbon fiber.
- The nanofibers may be disposed over the balloon in any of various ways. In some cases, the nanofibers are wound circumferentially around the body of the balloon. The nanofibers may be wound around the balloon loosely or under elastic tension. Where the nanofibers are wound around the balloon under elastic tension, the elastic tension may restrain the balloon in its unexpanded or folded configuration.
- For example,
FIGS. 13A-13C show PLGA nanofibers wrapped circumferentially around a balloon in its folded configuration.FIG. 13A shows a side view of the balloon;FIG. 13B shows a close-up view of a portion of the balloon, with the nanofibers being more visible; andFIG. 13C shows a scanning-electron micrograph of the nanofiber sheath showing the individual nanofibers. In another example,FIGS. 14A and 14B show PLGA nanofibers wrapped circumferentially around a balloon in its inflated configuration.FIG. 14A shows a side view of the balloon; andFIG. 14B shows a close-up view of a portion of the balloon, with the nanofibers being more visible. - In some cases, the nanofibers are deposited as a tangled mat on the balloon. In some of such cases, additional nanofibers may be wound circumferentially around the tangled mat of nanofibers (e.g., to encase the tangled mat of nanofibers).
- The nanofibers may be disposed over the balloon with the balloon in any suitable configuration (e.g., inflated or uninflated, folded or unfolded). The nanofibers may be disposed over the entire balloon or over only a portion of the balloon (e.g., between the cones).
- The therapeutic agent may be associated with the nanofiber sheath in any of various ways. The therapeutic agent may be provided in any suitable form, including as a liquid, a gel, or a solid. In some cases, the therapeutic agent is contained between the nanofiber sheath and the balloon (i.e., the sheath covers over the therapeutic agent). For example, the therapeutic agent can be deposited on the balloon and the nanofibers are spun (e.g., by electro-spinning) over the therapeutic agent to encase and protect it. Where the sheath comprises a tangled mat of nanofibers, the therapeutic agent may be dispersed within the network of nanofibers. In some cases, the therapeutic agent may be dispersed in the spaces between the nanofibers. In some cases, where the nanofibers are biodegradable (e.g., made of partially cured PEO), the therapeutic agent may constitute part of the composition of the nanofibers and be released upon degradation of the nanofibers. For example, the therapeutic agent may be contained in the nanofiber solution and spun with the nanofibers.
- Upon delivery of the balloon to the target site, the therapeutic agent may be released through any of various mechanisms. Where the nanofiber sheath covers over the therapeutic agent, the therapeutic agent may be released through gaps or openings between the nanofibers. For example, as the balloon expands, the therapeutic agent may be squeezed through such gaps or openings. In some cases, stretching of the nanofibers as the balloon expands causes thinning of the nanofibers. This thinning of the nanofibers increases the spacing between the nanofibers, providing openings for the release of the therapeutic agent.
- In addition to their role in delivery of the therapeutic agent, the nanofibers may also serve other functions. For example, elastic nanofibers may serve to control the folding or re-folding of the balloon or control the shape or dimensions of the expanded balloon.
- In another aspect of the present invention, the balloon includes a micro-electromechanical system (MEMS) for drug delivery. Various types of drug delivery systems using MEMS are known in the art, such as microfluidic devices that incorporate micropumps, valves, or flow channels; microfabricated porous membranes for drug encapsulation; microparticles for carrying drugs; and the microchip devices for drug delivery described in U.S. Pat. No. 6,656,162 (Santini et al.).
- Referring to
FIGS. 15A-15C , in this embodiment, a catheter device comprises a balloon having asubstrate layer 52 on the surface of theballoon wall 50.Substrate layer 52 has a plurality ofmicro-sized reservoirs 54 which contain atherapeutic agent 18.Reservoirs 54 are formed using any of various microfabrication techniques, including lithographic etching, molding, or micromachining (e.g., laser drilling). As such,substrate layer 52 is made of a material which can be shaped by microfabrication techniques, including for example, ceramics, metal oxides, semiconductor materials, and polymers.Reservoirs 54 haveopenings 55 through whichtherapeutic agent 18 may be released. To containtherapeutic agent 18 within thereservoirs 54 until the appropriate time for release,reservoirs 54 are covered byreservoir caps 56 formed of a shape memory material. Various types of shape memory material are suitable for use in reservoir caps 56, including shape memory polymers and shape memory alloys (e.g., nitinol). - In operation, the balloon is inserted into the body via a catheter. At the target site, as shown in
FIG. 15C , the balloon is inflated and reservoir caps 56 are actuated to open (e.g., by bending), allowingtherapeutic agent 18 contained inreservoirs 54 to be released. Reservoir caps 56 may be actuated in any of various ways, including temperature change or application of an electric current. - In certain embodiments of the invention, as described above, the configuration of the balloon and the sheath can be controlled such as to allow release of the therapeutic agent only at the desired time. For example, the device may be designed such that a certain pressure within the balloon is required for the sheath to release the therapeutic agent (e.g., by retracting, fracturing, fragmenting, opening pores, etc.). In this way, the therapeutic agent can be held in the folds while the device is delivered through the blood vessel to the target site. Then, at the target site, the balloon is inflated to the pressure and/or diameter at which the sheaths are designed to release the therapeutic agent. In this way, for example, the therapeutic agent release can be controlled such that it is released only if the balloon is in contact with or in close proximity to the vessel wall. This helps to prevent loss of the therapeutic agent during catheter placement and balloon inflation. Also, because deflation of the balloon can, in some instances, stop or substantially reduce therapeutic agent release, certain embodiments of the invention can control the duration of release after the initial release of therapeutic agent.
- Medical devices of the present invention may also include a vascular stent mounted on the balloon. The vascular stent may be any of those known in the art, including those with or without coatings that elute a therapeutic agent. The stent may also be biostable, bioerodible, or biodegradable.
- The balloons of the present invention may also be coated with a low-molecular weight carbohydrate, such as mannitol. The carbohydrate may be a separate coating or be blended with the therapeutic agent. The balloons of the present invention may also be coated with a radiocontrast agent (ionic or non-ionic), such as iopromide. The contrast agent may be a separate coating or be blended with the therapeutic agent.
- The therapeutic agent used in the present invention may be any pharmaceutically-acceptable agent such as a drug, a non-genetic therapeutic agent, a biomolecule, a small molecule, or cells. Example drugs include anti-proliferative agents or anti-restenosis agents such as paclitaxel, sirolimus (rapamycin), tacrolimus, everolimus, and zotarolimus.
- Exemplary non-genetic therapeutic agents include anti-thrombogenic agents such heparin, heparin derivatives, prostaglandin (including micellar prostaglandin E1), urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone); anti-proliferative agents such as enoxaparin, angiopeptin, sirolimus (rapamycin), tacrolimus, everolimus, zotarolimus, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid; anti-inflammatory agents such as dexamethasone, rosiglitazone, prednisolone, corticosterone, budesonide, estrogen, estrodiol, sulfasalazine, acetylsalicylic acid, mycophenolic acid, and mesalamine; anti-neoplastic/anti-proliferative/anti-mitotic agents such as paclitaxel, epothilone, cladribine, 5-fluorouracil, methotrexate, doxorubicin, daunorubicin, cyclosporine, cisplatin, vinblastine, vincristine, epothilones, endostatin, trapidil, halofuginone, and angiostatin; anti-cancer agents such as antisense inhibitors of c-myc oncogene; anti-microbial agents such as triclosan, cephalosporins, aminoglycosides, nitrofurantoin, silver ions, compounds, or salts; biofilm synthesis inhibitors such as non-steroidal anti-inflammatory agents and chelating agents such as ethylenediaminetetraacetic acid, O,O′-bis (2-aminoethyl) ethyleneglycol-N,N,N′,N′-tetraacetic acid and mixtures thereof; antibiotics such as gentamycin, rifampin, minocyclin, and ciprofloxacin; antibodies including chimeric antibodies and antibody fragments; anesthetic agents such as lidocaine, bupivacaine, and ropivacaine; nitric oxide; nitric oxide (NO) donors such as linsidomine, molsidomine, L-arginine, NO-carbohydrate adducts, polymeric or oligomeric NO adducts; anti-coagulants such as D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, enoxaparin, hirudin, warfarin sodium, Dicumarol, aspirin, prostaglandin inhibitors, platelet aggregation inhibitors such as cilostazol and tick antiplatelet factors; vascular cell growth promoters such as growth factors, transcriptional activators, and translational promoters; vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodilating agents; agents which interfere with endogenous vascoactive mechanisms; inhibitors of heat shock proteins such as geldanamycin; angiotensin converting enzyme (ACE) inhibitors; beta-blockers; βAR kinase (βARK) inhibitors; phospholamban inhibitors; protein-bound particle drugs such as ABRAXANE™; structural protein (e.g., collagen) cross-link breakers such as alagebrium (ALT-711); any combinations and prodrugs of the above.
- Exemplary biomolecules include peptides, polypeptides and proteins; oligonucleotides; nucleic acids such as double or single stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), and ribozymes; genes; carbohydrates; angiogenic factors including growth factors; cell cycle inhibitors; and anti-restenosis agents. Nucleic acids may be incorporated into delivery systems such as, for example, vectors (including viral vectors), plasmids or liposomes.
- Non-limiting examples of proteins include serca-2 protein, monocyte chemoattractant proteins (MCP-1) and bone morphogenic proteins (“BMP's”), such as, for example, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (VGR-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15. Preferred BMP's are any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, and BMP-7. These BMPs can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules. Alternatively, or in addition, molecules capable of inducing an upstream or downstream effect of a BMP can be provided. Such molecules include any of the “hedgehog” proteins, or the DNA's encoding them. Non-limiting examples of genes include survival genes that protect against cell death, such as anti-apoptotic Bcl-2 family factors and Akt kinase; serca 2 gene; and combinations thereof. Non-limiting examples of angiogenic factors include acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factors α and β, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α, hepatocyte growth factor, and insulin-like growth factor. A non-limiting example of a cell cycle inhibitor is a cathespin D (CD) inhibitor. Non-limiting examples of anti-restenosis agents include p15, p16, p18, p19, p21, p27, p53, p57, Rb, nFkB and E2F decoys, thymidine kinase and combinations thereof and other agents useful for interfering with cell proliferation.
- Exemplary small molecules include hormones, nucleotides, amino acids, sugars, and lipids and compounds have a molecular weight of less than 100 kD.
- Exemplary cells include stem cells, progenitor cells, endothelial cells, adult cardiomyocytes, and smooth muscle cells. Cells can be of human origin (autologous or allogenic) or from an animal source (xenogenic), or genetically engineered. Non-limiting examples of cells include side population (SP) cells, lineage negative (Lin−) cells including Lin− CD34−, Lin−CD34+, Lin−cKit+, mesenchymal stem cells including mesenchymal stem cells with 5-aza, cord blood cells, cardiac or other tissue derived stem cells, whole bone marrow, bone marrow mononuclear cells, endothelial progenitor cells, skeletal myoblasts or satellite cells, muscle derived cells, go cells, endothelial cells, adult cardiomyocytes, fibroblasts, smooth muscle cells, adult cardiac fibroblasts +5-aza, genetically modified cells, tissue engineered grafts, MyoD scar fibroblasts, pacing cells, embryonic stem cell clones, embryonic stem cells, fetal or neonatal cells, immunologically masked cells, and teratoma derived cells. Any of the therapeutic agents may be combined to the extent such combination is biologically compatible.
- The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Each of the disclosed aspects and embodiments of the present invention may be considered individually or in combination with other aspects, embodiments, and variations of the invention. Modifications of the disclosed embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art and such modifications are within the scope of the present invention.
Claims (18)
1. A medical device comprising:
a catheter;
a balloon mounted on the catheter;
a sheath disposed around the balloon, wherein the sheath has a plurality of weakened portions, wherein the weakened portions are arranged in a grid-like pattern or extend substantially radially along the sheath, and wherein the sheath is disrupted at one or more of the weakened portions when the balloon is expanded; and
a therapeutic agent disposed between the surface of the balloon and the sheath.
2. The medical device of claim 1 , wherein the weakened portions are perforation lines.
3. The medical device of claim 1 , wherein the weakened portions are arranged in a grid-like pattern.
4. The medical device of claim 3 , wherein the disruption of the sheath along the perforation lines creates fragments.
5. The medical device of claim 1 , wherein the weakened portions extend substantially radially along the sheath.
6. The medical device of claim 3 , wherein the size of at least some of the individual grid units are 100 μm or less.
7. The medical device of claim 4 , wherein at least some of the fragments have a size of 100 μm or less.
8. The medical device of claim 1 , wherein the weakened portions of the sheath are areas of the sheath that are attached to the balloon.
9. The medical device of claim 1 , wherein the weakened portions of the sheath have a different thickness or different composition that another portion of the sheath.
10. The medical device of claim 1 , wherein the therapeutic agent is provided as a patterned layer.
11. The medical device of claim 10 , wherein the patterned layer of therapeutic agent has ridges, and wherein the weakened portions of the sheath are over a ridge.
12. A method of medical treatment comprising:
inserting a medical device of claim 1 into a patient's blood vessel;
inflating the balloon;
disrupting the sheath at the weakened portions; and
releasing the therapeutic agent.
13. The method of claim 12 , wherein the weakened portions are perforation lines, wherein inflating the balloon causes tearing of the sheath along one or more of the perforation lines, and wherein the therapeutic agent is released through the tear in the sheath.
14. The method of claim 12 , wherein the weakened portions are arranged in a grid-like pattern, and wherein inflating the balloon causes fragmentation of the sheath.
15. The method of claim 14 , wherein the size of at least some of the fragments is 100 μm or less.
16. The method of claim 13 , wherein the weakened portions extend substantially radially along the sheath.
17. The method of claim 12 , wherein the weakened portions of the sheath are areas of the sheath that are attached to the balloon.
18. The method of claim 12 , wherein the weakened portions of the sheath have a different thickness or different composition that another portion of the sheath.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/179,054 US20110270226A1 (en) | 2008-03-06 | 2011-07-08 | Balloon catheter devices with sheath covering |
US13/289,490 US20120053517A1 (en) | 2008-03-06 | 2011-11-04 | Balloon catheter devices with sheath covering |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3432808P | 2008-03-06 | 2008-03-06 | |
US12/399,386 US20090227948A1 (en) | 2008-03-06 | 2009-03-06 | Balloon catheter devices with sheath covering |
US13/179,054 US20110270226A1 (en) | 2008-03-06 | 2011-07-08 | Balloon catheter devices with sheath covering |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/399,386 Division US20090227948A1 (en) | 2008-03-06 | 2009-03-06 | Balloon catheter devices with sheath covering |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/289,490 Division US20120053517A1 (en) | 2008-03-06 | 2011-11-04 | Balloon catheter devices with sheath covering |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110270226A1 true US20110270226A1 (en) | 2011-11-03 |
Family
ID=40578099
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/399,532 Abandoned US20090226502A1 (en) | 2008-03-06 | 2009-03-06 | Balloon catheter devices with solvent-swellable polymer |
US12/399,548 Expired - Fee Related US8114049B2 (en) | 2008-03-06 | 2009-03-06 | Balloon catheter devices with folded balloons |
US12/399,386 Abandoned US20090227948A1 (en) | 2008-03-06 | 2009-03-06 | Balloon catheter devices with sheath covering |
US13/179,054 Abandoned US20110270226A1 (en) | 2008-03-06 | 2011-07-08 | Balloon catheter devices with sheath covering |
US13/289,490 Abandoned US20120053517A1 (en) | 2008-03-06 | 2011-11-04 | Balloon catheter devices with sheath covering |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/399,532 Abandoned US20090226502A1 (en) | 2008-03-06 | 2009-03-06 | Balloon catheter devices with solvent-swellable polymer |
US12/399,548 Expired - Fee Related US8114049B2 (en) | 2008-03-06 | 2009-03-06 | Balloon catheter devices with folded balloons |
US12/399,386 Abandoned US20090227948A1 (en) | 2008-03-06 | 2009-03-06 | Balloon catheter devices with sheath covering |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/289,490 Abandoned US20120053517A1 (en) | 2008-03-06 | 2011-11-04 | Balloon catheter devices with sheath covering |
Country Status (5)
Country | Link |
---|---|
US (5) | US20090226502A1 (en) |
EP (4) | EP2262566A1 (en) |
JP (2) | JP2011513005A (en) |
CA (1) | CA2716985A1 (en) |
WO (3) | WO2009111716A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140371673A1 (en) * | 2012-01-24 | 2014-12-18 | Qualimed Innovative Medizinprodukte Gmbh | Balloon catheter |
CN104436421A (en) * | 2014-11-28 | 2015-03-25 | 刘宗军 | Medicine injectable balloon |
US20150190253A1 (en) * | 2007-11-05 | 2015-07-09 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Coated devices and methods of making coated devices that reduce smooth muscle cell proliferation and platelet activity |
US9415193B2 (en) | 2011-03-04 | 2016-08-16 | W. L. Gore & Associates, Inc. | Eluting medical devices |
US9901715B2 (en) | 2012-09-05 | 2018-02-27 | W. L. Gore Associates, Inc. | Retractable sheath devices, systems, and methods |
US20180353733A1 (en) * | 2015-06-12 | 2018-12-13 | Arravasc Limited | Delivery system for a drug coated angioplasty balloon |
US10668255B2 (en) | 2018-01-19 | 2020-06-02 | Medtronic Vascular, Inc. | Sheath for medically expandable balloon |
US10682492B2 (en) | 2018-01-19 | 2020-06-16 | Medtronic Vascular, Inc. | Expandable balloon sheath |
US10688287B2 (en) | 2018-01-19 | 2020-06-23 | Medtronic, Inc. | Sheath including sheath body and sheath insert |
US10702673B2 (en) | 2018-01-19 | 2020-07-07 | Medtronic Vascular, Inc. | Expandable balloon sheaths |
US10737071B2 (en) | 2018-01-19 | 2020-08-11 | Medtronic, Inc. | Splittable sheath |
US11123528B2 (en) | 2016-07-04 | 2021-09-21 | Kaneka Corporation | Balloon catheter and method for manufacturing same |
US11338115B2 (en) | 2016-09-30 | 2022-05-24 | Merit Medical Ireland Limited | Finned angioplasty balloon |
Families Citing this family (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8177743B2 (en) | 1998-05-18 | 2012-05-15 | Boston Scientific Scimed, Inc. | Localized delivery of drug agents |
WO2007011707A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
WO2007011708A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
CN101437571B (en) | 2005-10-13 | 2013-01-02 | 斯恩蒂斯有限公司 | Drug-impregnated encasement |
DE112007000906A5 (en) * | 2006-02-09 | 2009-01-15 | B. Braun Melsungen Ag | Fold balloon coating process |
PL2019657T3 (en) | 2006-04-26 | 2015-10-30 | Micell Technologies Inc | Coatings containing multiple drugs |
US20070282306A1 (en) * | 2006-06-05 | 2007-12-06 | Twincath, Llc | Multi-lumen catheter with protected tip |
US7777399B2 (en) * | 2006-07-31 | 2010-08-17 | Boston Scientific Scimed, Inc. | Medical balloon incorporating electroactive polymer and methods of making and using the same |
US9539593B2 (en) | 2006-10-23 | 2017-01-10 | Micell Technologies, Inc. | Holder for electrically charging a substrate during coating |
US8153181B2 (en) | 2006-11-14 | 2012-04-10 | Boston Scientific Scimed, Inc. | Medical devices and related methods |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US20080175887A1 (en) * | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
CA2679712C (en) | 2007-01-08 | 2016-11-15 | Micell Technologies, Inc. | Stents having biodegradable layers |
US8597720B2 (en) | 2007-01-21 | 2013-12-03 | Hemoteq Ag | Medical product for treating stenosis of body passages and for preventing threatening restenosis |
JP2010527746A (en) | 2007-05-25 | 2010-08-19 | ミセル テクノロジーズ、インコーポレイテッド | Polymer film for medical device coating |
US9192697B2 (en) | 2007-07-03 | 2015-11-24 | Hemoteq Ag | Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis |
WO2009111716A1 (en) | 2008-03-06 | 2009-09-11 | Boston Scientific Scimed, Inc. | Balloon catheter devices with sheath covering |
US9480826B2 (en) | 2008-03-21 | 2016-11-01 | Cagent Vascular, Llc | Intravascular device |
US11219750B2 (en) | 2008-03-21 | 2022-01-11 | Cagent Vascular, Inc. | System and method for plaque serration |
WO2009117158A2 (en) | 2008-03-21 | 2009-09-24 | Innovasc Llc | Device and method for opening blood vessels by pre-angioplasty serration and dilatation of aetherosclerotic plaque |
JP5601591B2 (en) * | 2008-04-09 | 2014-10-08 | リューベン,アレクサンダー | Method for producing a bioactive surface on a balloon of a balloon catheter and a balloon comprising a bioactive surface made by the method |
CN102083397B (en) | 2008-04-17 | 2013-12-25 | 米歇尔技术公司 | Stents having bioabsorbable layers |
US9126025B2 (en) * | 2008-05-01 | 2015-09-08 | Bayer Intellectual Property Gmbh | Method of coating a folded catheter balloon |
US9539381B2 (en) * | 2008-05-12 | 2017-01-10 | Humparkull, Llc | Hemostatic devices and methods for use thereof |
US10426483B2 (en) | 2008-05-12 | 2019-10-01 | Mitchell R. Humphreys | Hemostatic devices and methods for use thereof |
US9486431B2 (en) | 2008-07-17 | 2016-11-08 | Micell Technologies, Inc. | Drug delivery medical device |
US8968239B2 (en) * | 2008-09-02 | 2015-03-03 | Jose E. Herrera | Catheter device for the dynamic regulation of the venous return to the heart for the treatment of patients with heart failure |
US8114429B2 (en) | 2008-09-15 | 2012-02-14 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US8257722B2 (en) | 2008-09-15 | 2012-09-04 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US9198968B2 (en) | 2008-09-15 | 2015-12-01 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US8128951B2 (en) | 2008-09-15 | 2012-03-06 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
WO2010080575A2 (en) * | 2008-12-18 | 2010-07-15 | Michal Konstantino | Method and apparatus for transport of substances into body tissue |
US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
US9981072B2 (en) | 2009-04-01 | 2018-05-29 | Micell Technologies, Inc. | Coated stents |
WO2010120620A1 (en) * | 2009-04-13 | 2010-10-21 | Cook Incorporated | Coated balloon catheter |
WO2010121187A2 (en) | 2009-04-17 | 2010-10-21 | Micell Techologies, Inc. | Stents having controlled elution |
EP2243501A1 (en) * | 2009-04-24 | 2010-10-27 | Eurocor Gmbh | Shellac and paclitaxel coated catheter balloons |
US20100285085A1 (en) * | 2009-05-07 | 2010-11-11 | Abbott Cardiovascular Systems Inc. | Balloon coating with drug transfer control via coating thickness |
ES2550634T3 (en) | 2009-07-10 | 2015-11-11 | Boston Scientific Scimed, Inc. | Use of nanocrystals for a drug delivery balloon |
EP2453834A4 (en) | 2009-07-16 | 2014-04-16 | Micell Technologies Inc | Drug delivery medical device |
WO2011008393A2 (en) | 2009-07-17 | 2011-01-20 | Boston Scientific Scimed, Inc. | Nucleation of drug delivery balloons to provide improved crystal size and density |
WO2011028419A1 (en) * | 2009-08-27 | 2011-03-10 | Boston Scientific Scimed, Inc. | Balloon catheter devices with drug-coated sheath |
US20120232640A1 (en) | 2009-11-19 | 2012-09-13 | Blue Medical Devices Bv | Narrow profile composition-releasing expandable medical balloon catheter |
US20110178503A1 (en) * | 2010-01-21 | 2011-07-21 | Boston Scientific Scimed, Inc. | Balloon catheters with therapeutic agent in balloon folds and methods of making the same |
EP2531140B1 (en) | 2010-02-02 | 2017-11-01 | Micell Technologies, Inc. | Stent and stent delivery system with improved deliverability |
US9199066B2 (en) | 2010-03-12 | 2015-12-01 | Quattro Vascular Pte Ltd. | Device and method for compartmental vessel treatment |
US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
US10232092B2 (en) | 2010-04-22 | 2019-03-19 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
EP2575591A4 (en) * | 2010-06-03 | 2017-09-13 | The General Hospital Corporation | Apparatus and method for devices for imaging structures in or at one or more luminal organs |
US20110301565A1 (en) * | 2010-06-07 | 2011-12-08 | Boston Scientific Scimed, Inc. | Medical balloons having a sheath designed to facilitate release of therapeutic agent |
CA2803095C (en) | 2010-06-30 | 2020-08-11 | Surmodics, Inc. | Catheter assembly sleeve having a plurality of openings |
CA2805631C (en) | 2010-07-16 | 2018-07-31 | Micell Technologies, Inc. | Drug delivery medical device |
WO2012026717A2 (en) * | 2010-08-25 | 2012-03-01 | (주)이화바이오메딕스 | Balloon catheter in which film for drug delivery is provided |
WO2012031236A1 (en) | 2010-09-02 | 2012-03-08 | Boston Scientific Scimed, Inc. | Coating process for drug delivery balloons using heat-induced rewrap memory |
US10780251B2 (en) * | 2010-09-17 | 2020-09-22 | W. L. Gore & Associates, Inc. | Expandable medical devices |
US8961457B2 (en) * | 2010-09-30 | 2015-02-24 | Surmodics, Inc. | Catheter assembly with guard |
CA2821728A1 (en) | 2010-12-16 | 2012-06-21 | Ams Research Corporation | Micro-needle bladder balloon |
US9724729B2 (en) * | 2010-12-22 | 2017-08-08 | Abbott Laboratories | Method of modifying a coating on a medical device |
WO2012149328A1 (en) * | 2011-04-29 | 2012-11-01 | Boston Scientific Scimed, Inc. | Protective surfaces for drug-coated medical devices |
US8795228B2 (en) * | 2011-05-05 | 2014-08-05 | Boston Scientific Scimed, Inc. | Drug delivery device with sheath for improved drug delivery |
US10464100B2 (en) | 2011-05-31 | 2019-11-05 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
US10016579B2 (en) | 2011-06-23 | 2018-07-10 | W.L. Gore & Associates, Inc. | Controllable inflation profile balloon cover apparatus |
US20220032015A1 (en) * | 2011-06-23 | 2022-02-03 | W. L. Gore & Associates, Inc. | Controllable inflation profile balloon cover methods |
US9370643B2 (en) * | 2011-06-23 | 2016-06-21 | W.L. Gore & Associates, Inc. | High strength balloon cover |
US9370647B2 (en) * | 2011-07-14 | 2016-06-21 | W. L. Gore & Associates, Inc. | Expandable medical devices |
US10117972B2 (en) | 2011-07-15 | 2018-11-06 | Micell Technologies, Inc. | Drug delivery medical device |
US20130030406A1 (en) | 2011-07-26 | 2013-01-31 | Medtronic Vascular, Inc. | Textured Dilatation Balloon and Methods |
WO2013022458A1 (en) | 2011-08-05 | 2013-02-14 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
US9056152B2 (en) | 2011-08-25 | 2015-06-16 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
US9730726B2 (en) | 2011-10-07 | 2017-08-15 | W. L. Gore & Associates, Inc. | Balloon assemblies having controllably variable topographies |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
TWI590843B (en) | 2011-12-28 | 2017-07-11 | 信迪思有限公司 | Films and methods of manufacture |
SG11201403991RA (en) | 2012-02-01 | 2014-09-26 | Quattro Vascular Pte Ltd | Device for compartmental dilatation of blood vessels |
US9216033B2 (en) * | 2012-02-08 | 2015-12-22 | Quattro Vascular Pte Ltd. | System and method for treating biological vessels |
SG11201403915XA (en) | 2012-02-08 | 2014-08-28 | Quattro Vascular Pte Ltd | Constraining structure with non-linear axial struts |
IN2014DN07117A (en) * | 2012-03-09 | 2015-04-24 | Clearstream Tech Ltd | |
CN104271191B (en) * | 2012-05-08 | 2017-06-06 | 昊朗科技(佛山)有限公司 | Transmission and sensor based on hydrogel |
US9381326B2 (en) * | 2012-06-15 | 2016-07-05 | W. L. Gore & Associates, Inc. | Vascular occlusion and drug delivery devices, systems, and methods |
US9956385B2 (en) | 2012-06-28 | 2018-05-01 | The Spectranetics Corporation | Post-processing of a medical device to control morphology and mechanical properties |
JP6162932B2 (en) * | 2012-06-29 | 2017-07-12 | フクダ電子株式会社 | Balloon catheter and balloon catheter manufacturing method |
US10806830B2 (en) | 2012-10-26 | 2020-10-20 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
WO2020172560A1 (en) | 2019-02-22 | 2020-08-27 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
CN104936629A (en) | 2012-10-26 | 2015-09-23 | 优敦力公司 | Drug coated balloon catheters for nonvascular strictures |
US10898700B2 (en) | 2012-10-26 | 2021-01-26 | Urotronic, Inc. | Balloon catheters for body lumens |
US10850076B2 (en) | 2012-10-26 | 2020-12-01 | Urotronic, Inc. | Balloon catheters for body lumens |
US10881839B2 (en) | 2012-10-26 | 2021-01-05 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US11938287B2 (en) | 2012-10-26 | 2024-03-26 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US11504450B2 (en) | 2012-10-26 | 2022-11-22 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US10010654B2 (en) | 2012-10-30 | 2018-07-03 | W. L. Gore & Associates, Inc. | Sleeve for medical device assembly |
US20140171912A1 (en) * | 2012-12-18 | 2014-06-19 | California Institute Of Technology | Drug-eluting angioplasty balloon systems |
US20140243846A1 (en) * | 2013-02-26 | 2014-08-28 | Cook Medical Technologies Llc | Balloon Catheter and Method of Use Thereof |
WO2014133708A1 (en) * | 2013-02-26 | 2014-09-04 | Cook Medical Technologies Llc | Balloon catheter |
EP2967803B1 (en) | 2013-03-12 | 2023-12-27 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
US9669194B2 (en) | 2013-03-14 | 2017-06-06 | W. L. Gore & Associates, Inc. | Conformable balloon devices and methods |
JP6090852B2 (en) * | 2013-04-02 | 2017-03-08 | テルモ株式会社 | Balloon catheter |
US10449335B2 (en) * | 2013-05-03 | 2019-10-22 | C.R. Bard, Inc. | Peelable protective sheath |
WO2014186532A1 (en) | 2013-05-15 | 2014-11-20 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
EP3010560B1 (en) | 2013-06-21 | 2020-01-01 | DePuy Synthes Products, Inc. | Films and methods of manufacture |
WO2015103097A1 (en) * | 2014-01-02 | 2015-07-09 | Boston Scientific Scimed, Inc. | Drug eluting balloon with preferred drug orientation to improve drug transfer efficiency |
US10525171B2 (en) | 2014-01-24 | 2020-01-07 | The Spectranetics Corporation | Coatings for medical devices |
US10463842B2 (en) | 2014-06-04 | 2019-11-05 | Cagent Vascular, Llc | Cage for medical balloon |
US20150367112A1 (en) * | 2014-06-20 | 2015-12-24 | Daniel Gelbart | Medical Balloon with Reduced Straightening Force |
JP5758029B1 (en) * | 2014-06-25 | 2015-08-05 | 日出夫 文山 | Body fluid flow non-blocking balloon catheter |
EP3200860B1 (en) * | 2014-10-02 | 2021-01-13 | Alexander Rübben | Cutback method for intravascular dilation catheter |
WO2016061692A1 (en) * | 2014-10-22 | 2016-04-28 | Jmd Innovation | Anti-adhesion intrauterine balloon |
WO2016073511A1 (en) * | 2014-11-03 | 2016-05-12 | Cagent Vascular, Llc | Medical balloon |
US10471238B2 (en) | 2014-11-03 | 2019-11-12 | Cagent Vascular, Llc | Serration balloon |
CN107106822B (en) | 2014-11-17 | 2021-05-04 | 特里雷米医疗有限责任公司 | Balloon catheter system |
KR101663805B1 (en) | 2014-12-03 | 2016-10-14 | 연세대학교 산학협력단 | Balloon Catheter Having Micro Needles and Manufacturing Method Thereof |
WO2016118923A1 (en) * | 2015-01-22 | 2016-07-28 | Intersect Ent, Inc. | Drug-coated balloon |
US11904072B2 (en) | 2015-04-24 | 2024-02-20 | Urotronic, Inc. | Drug coated balloon catheters for nonvascular strictures |
CN118320191A (en) | 2015-04-24 | 2024-07-12 | 优敦力公司 | Drug coated balloon catheter for non-vascular stenosis |
JP6227193B2 (en) * | 2015-07-22 | 2017-11-08 | オリンパス株式会社 | Endoscopic treatment tool |
US10166374B2 (en) | 2015-09-17 | 2019-01-01 | Cagent Vascular, Llc | Wedge dissectors for a medical balloon |
US10105519B2 (en) * | 2015-10-20 | 2018-10-23 | C.R. Bard, Inc. | Variable diameter medical balloon |
JP6788964B2 (en) * | 2015-11-26 | 2020-11-25 | フクダ電子株式会社 | Catheter Balloon manufacturing method and balloon catheter |
US10792477B2 (en) * | 2016-02-08 | 2020-10-06 | Orbusneich Medical Pte. Ltd. | Drug eluting balloon |
EP3413964A4 (en) * | 2016-02-08 | 2019-12-04 | Orbusneich Medical Pte. Ltd | Drug eluting balloon |
EP3406294B1 (en) * | 2016-03-23 | 2023-06-28 | Terumo Kabushiki Kaisha | Balloon catheter and production method therefor, and treatment method |
CN110177522B (en) * | 2016-10-05 | 2021-07-30 | 泰尔茂株式会社 | Balloon catheter system |
JP2018068724A (en) * | 2016-10-31 | 2018-05-10 | 株式会社カネカ | Balloon catheter |
CA3044046A1 (en) | 2016-11-16 | 2018-05-24 | Cagent Vascular, Llc | Systems and methods of depositing drug into tissue through serrations |
JP6726172B2 (en) * | 2016-11-22 | 2020-07-22 | 朝日インテック株式会社 | Balloon catheter |
US11826492B2 (en) | 2016-12-22 | 2023-11-28 | Biotronik Ag | Intratumoral drug delivery materials and methods for treating breast cancer |
JP2021036924A (en) * | 2017-12-27 | 2021-03-11 | テルモ株式会社 | Balloon catheter |
CN108187212B (en) * | 2018-03-14 | 2022-07-15 | 董鹏 | Medicine balloon |
US10935149B2 (en) | 2018-03-15 | 2021-03-02 | University Of Washington | Temperature-actuated valve, fluidic device, and related methods of use |
WO2019182131A1 (en) * | 2018-03-23 | 2019-09-26 | テルモ株式会社 | Medical device and method of applying medicament |
EP3826707A4 (en) | 2018-07-25 | 2022-05-18 | Cagent Vascular, Inc. | Medical balloon catheters with enhanced pushability |
US11389627B1 (en) | 2018-10-02 | 2022-07-19 | Lutonix Inc. | Balloon protectors, balloon-catheter assemblies, and methods thereof |
US11672959B2 (en) | 2019-01-18 | 2023-06-13 | Intersect Ent, Inc. | Expandable member systems and methods for drug delivery |
CN112089951A (en) * | 2019-06-18 | 2020-12-18 | 微创神通医疗科技(上海)有限公司 | Medical balloon, balloon catheter and medical device |
WO2021103650A1 (en) * | 2019-11-25 | 2021-06-03 | 丁海雁 | Balloon assembly and medical device comprising same |
WO2021161545A1 (en) * | 2020-02-14 | 2021-08-19 | 日本ライフライン株式会社 | Drug delivery balloon catheter |
CN111298274B (en) * | 2020-05-14 | 2020-09-22 | 上海脉全医疗器械有限公司 | Medicine balloon and using method thereof |
CN113350648A (en) * | 2021-07-18 | 2021-09-07 | 温州医科大学附属第一医院 | Tracheal catheter capable of accurately local anesthesia |
WO2024106083A1 (en) * | 2022-11-16 | 2024-05-23 | 株式会社カネカ | Balloon for balloon catheter, and balloon catheter |
WO2024106084A1 (en) * | 2022-11-16 | 2024-05-23 | 株式会社カネカ | Balloon for balloon catheter and balloon catheter |
CN117482365B (en) * | 2023-12-27 | 2024-04-09 | 杭州德晋医疗科技有限公司 | Balloon dilation catheter |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5707385A (en) * | 1994-11-16 | 1998-01-13 | Advanced Cardiovascular Systems, Inc. | Drug loaded elastic membrane and method for delivery |
US6010480A (en) * | 1993-08-23 | 2000-01-04 | Boston Scientific Corporation | Balloon catheter |
Family Cites Families (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4417576A (en) * | 1982-02-25 | 1983-11-29 | Baran Ostap E | Double-wall surgical cuff |
US4423725A (en) * | 1982-03-31 | 1984-01-03 | Baran Ostap E | Multiple surgical cuff |
SU1069826A1 (en) | 1982-09-17 | 1984-01-30 | Запорожский медицинский институт | Endotracheal tube |
US4748982A (en) * | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
US5042976A (en) * | 1987-01-13 | 1991-08-27 | Terumo Kabushiki Kaisha | Balloon catheter and manufacturing method of the same |
DE3821544C2 (en) * | 1988-06-25 | 1994-04-28 | H Prof Dr Med Just | Dilatation catheter |
US5749915A (en) * | 1988-08-24 | 1998-05-12 | Focal, Inc. | Polymeric endoluminal paving process |
DK170965B1 (en) * | 1988-08-31 | 1996-04-09 | Meadox Medicals Inc | dilatation catheter |
US5226913A (en) * | 1988-09-01 | 1993-07-13 | Corvita Corporation | Method of making a radially expandable prosthesis |
EP0550425B1 (en) * | 1988-10-28 | 1996-07-17 | Kanji Inoue | Balloon catheter assembly |
US5091205A (en) * | 1989-01-17 | 1992-02-25 | Union Carbide Chemicals & Plastics Technology Corporation | Hydrophilic lubricious coatings |
US5015231A (en) * | 1989-04-21 | 1991-05-14 | Scimed Life Systems, Inc. | Multipart split sleeve balloon protector for dilatation catheter |
US4994033A (en) * | 1989-05-25 | 1991-02-19 | Schneider (Usa) Inc. | Intravascular drug delivery dilatation catheter |
US5304121A (en) * | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5674192A (en) * | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
US5843089A (en) * | 1990-12-28 | 1998-12-01 | Boston Scientific Corporation | Stent lining |
US5049132A (en) * | 1990-01-08 | 1991-09-17 | Cordis Corporation | Balloon catheter for delivering therapeutic agents |
US5141494A (en) * | 1990-02-15 | 1992-08-25 | Danforth Biomedical, Inc. | Variable wire diameter angioplasty dilatation balloon catheter |
US5545208A (en) * | 1990-02-28 | 1996-08-13 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US5092841A (en) * | 1990-05-17 | 1992-03-03 | Wayne State University | Method for treating an arterial wall injured during angioplasty |
US5190540A (en) * | 1990-06-08 | 1993-03-02 | Cardiovascular & Interventional Research Consultants, Inc. | Thermal balloon angioplasty |
US5498238A (en) * | 1990-06-15 | 1996-03-12 | Cortrak Medical, Inc. | Simultaneous angioplasty and phoretic drug delivery |
US5499971A (en) * | 1990-06-15 | 1996-03-19 | Cortrak Medical, Inc. | Method for iontophoretically delivering drug adjacent to a heart |
US5196024A (en) * | 1990-07-03 | 1993-03-23 | Cedars-Sinai Medical Center | Balloon catheter with cutting edge |
US5324261A (en) * | 1991-01-04 | 1994-06-28 | Medtronic, Inc. | Drug delivery balloon catheter with line of weakness |
US5102402A (en) * | 1991-01-04 | 1992-04-07 | Medtronic, Inc. | Releasable coatings on balloon catheters |
US5893840A (en) * | 1991-01-04 | 1999-04-13 | Medtronic, Inc. | Releasable microcapsules on balloon catheters |
CA2104121C (en) * | 1991-04-24 | 1998-12-22 | Blair D. Walker | Exchangeable integrated-wire balloon catheter |
US5195969A (en) * | 1991-04-26 | 1993-03-23 | Boston Scientific Corporation | Co-extruded medical balloons and catheter using such balloons |
US5213576A (en) * | 1991-06-11 | 1993-05-25 | Cordis Corporation | Therapeutic porous balloon catheter |
US5295959A (en) * | 1992-03-13 | 1994-03-22 | Medtronic, Inc. | Autoperfusion dilatation catheter having a bonded channel |
US5501662A (en) * | 1992-05-22 | 1996-03-26 | Genetronics, Inc. | Implantable electroporation method and apparatus for drug and gene delivery |
US5383928A (en) * | 1992-06-10 | 1995-01-24 | Emory University | Stent sheath for local drug delivery |
US5507724A (en) * | 1992-07-01 | 1996-04-16 | Genetronics, Inc. | Electroporation and iontophoresis apparatus and method for insertion of drugs and genes into cells |
DE4222380A1 (en) * | 1992-07-08 | 1994-01-13 | Ernst Peter Prof Dr M Strecker | Endoprosthesis implantable percutaneously in a patient's body |
US5447497A (en) * | 1992-08-06 | 1995-09-05 | Scimed Life Systems, Inc | Balloon catheter having nonlinear compliance curve and method of using |
US5348538A (en) | 1992-09-29 | 1994-09-20 | Scimed Life Systems, Inc. | Shrinking balloon catheter having nonlinear or hybrid compliance curve |
US5352236A (en) * | 1992-09-29 | 1994-10-04 | Medtronic, Inc. | Balloon protector |
US5634901A (en) * | 1992-11-02 | 1997-06-03 | Localmed, Inc. | Method of using a catheter sleeve |
US5336178A (en) * | 1992-11-02 | 1994-08-09 | Localmed, Inc. | Intravascular catheter with infusion array |
US5807306A (en) * | 1992-11-09 | 1998-09-15 | Cortrak Medical, Inc. | Polymer matrix drug delivery apparatus |
WO1994021308A1 (en) * | 1993-03-18 | 1994-09-29 | Cedars-Sinai Medical Center | Drug incorporating and releasing polymeric coating for bioprosthesis |
WO1994023787A1 (en) | 1993-04-22 | 1994-10-27 | Rammler David H | Sampling balloon catheter |
US5464650A (en) * | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
DE4324218A1 (en) * | 1993-07-19 | 1995-01-26 | Bavaria Med Tech | Cuff catheter |
US6027779A (en) * | 1993-08-18 | 2000-02-22 | W. L. Gore & Associates, Inc. | Thin-wall polytetrafluoroethylene tube |
US5735892A (en) * | 1993-08-18 | 1998-04-07 | W. L. Gore & Associates, Inc. | Intraluminal stent graft |
EP0746362B1 (en) * | 1993-08-23 | 2002-01-16 | Boston Scientific Corporation | Improved balloon catheter |
US5738901A (en) * | 1993-09-20 | 1998-04-14 | Scimed Life Systems, Inc. | Catheter balloon with retraction coating |
US5397307A (en) * | 1993-12-07 | 1995-03-14 | Schneider (Usa) Inc. | Drug delivery PTCA catheter and method for drug delivery |
US5545132A (en) * | 1993-12-21 | 1996-08-13 | C. R. Bard, Inc. | Helically grooved balloon for dilatation catheter and method of using |
US5599306A (en) * | 1994-04-01 | 1997-02-04 | Localmed, Inc. | Method and apparatus for providing external perfusion lumens on balloon catheters |
US5456666A (en) * | 1994-04-26 | 1995-10-10 | Boston Scientific Corp | Medical balloon folding into predetermined shapes and method |
US5505700A (en) * | 1994-06-14 | 1996-04-09 | Cordis Corporation | Electro-osmotic infusion catheter |
US5601589A (en) | 1994-06-29 | 1997-02-11 | General Surgical Innovations, Inc. | Extraluminal balloon dissection apparatus and method |
US5554120A (en) * | 1994-07-25 | 1996-09-10 | Advanced Cardiovascular Systems, Inc. | Polymer blends for use in making medical devices including catheters and balloons for dilatation catheters |
US5653689A (en) * | 1995-09-30 | 1997-08-05 | Abacus Design & Development, Inc. | Infusion catheter |
US6124007A (en) * | 1996-03-06 | 2000-09-26 | Scimed Life Systems Inc | Laminate catheter balloons with additive burst strength and methods for preparation of same |
DE69723137T2 (en) * | 1996-03-18 | 2004-05-27 | Ashiya, Hiroaki | Catheteranordnung |
US5707358A (en) * | 1996-05-13 | 1998-01-13 | Wright; John T. M. | Dual concentric balloon catheter for retrograde cardioplegia perfusion |
US5833659A (en) * | 1996-07-10 | 1998-11-10 | Cordis Corporation | Infusion balloon catheter |
US5868707A (en) * | 1996-08-15 | 1999-02-09 | Advanced Cardiovascular Systems, Inc. | Protective sheath for catheter balloons |
US5704908A (en) * | 1996-10-10 | 1998-01-06 | Genetronics, Inc. | Electroporation and iontophoresis catheter with porous balloon |
EP0835673A3 (en) | 1996-10-10 | 1998-09-23 | Schneider (Usa) Inc. | Catheter for tissue dilatation and drug delivery |
US5833651A (en) * | 1996-11-08 | 1998-11-10 | Medtronic, Inc. | Therapeutic intraluminal stents |
US5730734A (en) * | 1996-11-14 | 1998-03-24 | Scimed Life Systems, Inc. | Catheter systems with interchangeable parts |
US6306166B1 (en) * | 1997-08-13 | 2001-10-23 | Scimed Life Systems, Inc. | Loading and release of water-insoluble drugs |
US5866561A (en) * | 1997-08-21 | 1999-02-02 | Scimed Life Systems, Inc. | Local delivery of estrogen for angiogenesis |
US5928193A (en) * | 1997-10-03 | 1999-07-27 | Boston Scientific Corporation | Balloon catheterization |
US6364856B1 (en) * | 1998-04-14 | 2002-04-02 | Boston Scientific Corporation | Medical device with sponge coating for controlled drug release |
US6450989B2 (en) * | 1998-04-27 | 2002-09-17 | Artemis Medical, Inc. | Dilating and support apparatus with disease inhibitors and methods for use |
US6206283B1 (en) * | 1998-12-23 | 2001-03-27 | At&T Corp. | Method and apparatus for transferring money via a telephone call |
US6280411B1 (en) * | 1998-05-18 | 2001-08-28 | Scimed Life Systems, Inc. | Localized delivery of drug agents |
US8177743B2 (en) * | 1998-05-18 | 2012-05-15 | Boston Scientific Scimed, Inc. | Localized delivery of drug agents |
US6369039B1 (en) * | 1998-06-30 | 2002-04-09 | Scimed Life Sytems, Inc. | High efficiency local drug delivery |
US6652581B1 (en) * | 1998-07-07 | 2003-11-25 | Boston Scientific Scimed, Inc. | Medical device with porous surface for controlled drug release and method of making the same |
US6299980B1 (en) * | 1998-09-29 | 2001-10-09 | Medtronic Ave, Inc. | One step lubricious coating |
US6129706A (en) * | 1998-12-10 | 2000-10-10 | Janacek; Jaroslav | Corrugated catheter balloon |
US6593130B1 (en) * | 1999-04-16 | 2003-07-15 | The Regents Of The University Of California | Method and apparatus for ex vivo and in vivo cellular electroporation of gene protein or drug therapy |
JP2001009037A (en) | 1999-06-25 | 2001-01-16 | Terumo Corp | Balloon for dilation of narrow segment and balloon catheter |
DE19933279A1 (en) * | 1999-07-14 | 2001-03-01 | Biotronik Mess & Therapieg | Polymer blend useful for medical instruments such as balloon catheters, comprises partially crystalline polyamide polymer and a polystyrene thermoplastic elastomer flexibilizing agent |
US6733513B2 (en) | 1999-11-04 | 2004-05-11 | Advanced Bioprosthetic Surfaces, Ltd. | Balloon catheter having metal balloon and method of making same |
EP1690527B1 (en) | 1999-11-17 | 2015-01-07 | Boston Scientific Limited | Microfabricated devices for the delivery of molecules into a carrier fluid |
US6544221B1 (en) * | 2000-08-30 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Balloon designs for drug delivery |
US6638246B1 (en) * | 2000-11-28 | 2003-10-28 | Scimed Life Systems, Inc. | Medical device for delivery of a biologically active material to a lumen |
US6544223B1 (en) * | 2001-01-05 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Balloon catheter for delivering therapeutic agents |
US6547803B2 (en) * | 2001-09-20 | 2003-04-15 | The Regents Of The University Of California | Microfabricated surgical device for interventional procedures |
US20030077310A1 (en) * | 2001-10-22 | 2003-04-24 | Chandrashekhar Pathak | Stent coatings containing HMG-CoA reductase inhibitors |
US6656155B2 (en) * | 2001-12-17 | 2003-12-02 | Scimed Life Systems, Inc. | Catheter for endoluminal delivery of therapeutic agents that minimizes loss of therapeutic |
US6743388B2 (en) * | 2001-12-31 | 2004-06-01 | Advanced Cardiovascular Systems, Inc. | Process of making polymer articles |
US7758605B2 (en) * | 2002-02-28 | 2010-07-20 | Boston Scientific Scimed, Inc. | Balloon folding apparatus, methods and products |
WO2004014448A1 (en) * | 2002-08-13 | 2004-02-19 | Medtronic, Inc. | Active agent delivery system including a hydrophilic polymer, medical device, and method |
US6991617B2 (en) * | 2002-08-21 | 2006-01-31 | Hektner Thomas R | Vascular treatment method and device |
DE10244847A1 (en) * | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medical device for drug delivery |
US7048714B2 (en) * | 2002-10-30 | 2006-05-23 | Biorest Ltd. | Drug eluting medical device with an expandable portion for drug release |
WO2004060471A1 (en) | 2003-01-02 | 2004-07-22 | Novoste Corporation | Drug delivery balloon catheter |
US7081113B2 (en) * | 2003-06-26 | 2006-07-25 | Depuy Acromed, Inc. | Helical probe |
US8025637B2 (en) * | 2003-07-18 | 2011-09-27 | Boston Scientific Scimed, Inc. | Medical balloons and processes for preparing same |
US7364585B2 (en) * | 2003-08-11 | 2008-04-29 | Boston Scientific Scimed, Inc. | Medical devices comprising drug-loaded capsules for localized drug delivery |
US7166099B2 (en) | 2003-08-21 | 2007-01-23 | Boston Scientific Scimed, Inc. | Multilayer medical devices |
WO2005027996A2 (en) | 2003-09-15 | 2005-03-31 | Atrium Medical Corporation | Application of a therapeutic substance to a tissue location using an expandable medical device |
WO2005039664A2 (en) | 2003-10-14 | 2005-05-06 | Cube Medical A/S | Medical device with electrospun nanofibers |
US20050228417A1 (en) * | 2004-03-26 | 2005-10-13 | Teitelbaum George P | Devices and methods for removing a matter from a body cavity of a patient |
JP4443278B2 (en) | 2004-03-26 | 2010-03-31 | テルモ株式会社 | Catheter with expansion body |
US20070232996A1 (en) * | 2004-04-29 | 2007-10-04 | Cube Medical A/S | Balloon for Use in Angioplasty with an Outer Layer of Nanofibers |
ES2310357T3 (en) * | 2004-05-21 | 2009-01-01 | Medtronic Vascular, Inc. | BALLED BALLOONS FOR CATETER. |
US20050273049A1 (en) * | 2004-06-08 | 2005-12-08 | Peter Krulevitch | Drug delivery device using microprojections |
EP1773439A4 (en) * | 2004-07-14 | 2010-01-20 | By Pass Inc | Material delivery system |
US20060025848A1 (en) * | 2004-07-29 | 2006-02-02 | Jan Weber | Medical device having a coating layer with structural elements therein and method of making the same |
US7491188B2 (en) * | 2004-10-12 | 2009-02-17 | Boston Scientific Scimed, Inc. | Reinforced and drug-eluting balloon catheters and methods for making same |
US20060127442A1 (en) * | 2004-12-09 | 2006-06-15 | Helmus Michael N | Use of supercritical fluids to incorporate biologically active agents into nanoporous medical articles |
US8202245B2 (en) | 2005-01-26 | 2012-06-19 | Boston Scientific Scimed, Inc. | Medical devices and methods of making the same |
US8048028B2 (en) | 2005-02-17 | 2011-11-01 | Boston Scientific Scimed, Inc. | Reinforced medical balloon |
US8672990B2 (en) * | 2005-05-27 | 2014-03-18 | Boston Scientific Scimed, Inc. | Fiber mesh controlled expansion balloon catheter |
US8795348B2 (en) | 2005-06-14 | 2014-08-05 | Boston Scientific Scimed, Inc. | Medical devices and related methods |
US8123770B2 (en) | 2005-11-01 | 2012-02-28 | Cook Medical Technologies Llc | Angioplasty cutting device and method for treating a stenotic lesion in a body vessel |
US20070112300A1 (en) * | 2005-11-14 | 2007-05-17 | Roman Ricardo D | Balloon folding design, apparatus and method of making the same |
US20070184085A1 (en) * | 2006-02-03 | 2007-08-09 | Boston Scientific Scimed, Inc. | Ultrasound activated medical device |
DE112007000906A5 (en) * | 2006-02-09 | 2009-01-15 | B. Braun Melsungen Ag | Fold balloon coating process |
US20070191811A1 (en) * | 2006-02-10 | 2007-08-16 | Joseph Berglund | System and Method for Treating a Vascular Condition |
US7572625B2 (en) * | 2006-05-18 | 2009-08-11 | Boston Scientific Scimed, Inc. | Medical devices coated with drug carrier macromolecules |
US20080097300A1 (en) * | 2006-08-07 | 2008-04-24 | Sherif Eskaros | Catheter balloon with multiple micropleats |
US20080033476A1 (en) * | 2006-08-07 | 2008-02-07 | Greene Joel M | Catheter balloon with controlled failure sheath |
US20080140002A1 (en) * | 2006-12-06 | 2008-06-12 | Kamal Ramzipoor | System for delivery of biologically active substances with actuating three dimensional surface |
US8597720B2 (en) | 2007-01-21 | 2013-12-03 | Hemoteq Ag | Medical product for treating stenosis of body passages and for preventing threatening restenosis |
US9370642B2 (en) | 2007-06-29 | 2016-06-21 | J.W. Medical Systems Ltd. | Adjustable-length drug delivery balloon |
US20090105687A1 (en) | 2007-10-05 | 2009-04-23 | Angioscore, Inc. | Scoring catheter with drug delivery membrane |
WO2009111716A1 (en) | 2008-03-06 | 2009-09-11 | Boston Scientific Scimed, Inc. | Balloon catheter devices with sheath covering |
EP2106820A1 (en) | 2008-03-31 | 2009-10-07 | Torsten Heilmann | Expansible biocompatible coats comprising a biologically active substance |
WO2011028419A1 (en) * | 2009-08-27 | 2011-03-10 | Boston Scientific Scimed, Inc. | Balloon catheter devices with drug-coated sheath |
-
2009
- 2009-03-06 WO PCT/US2009/036359 patent/WO2009111716A1/en active Application Filing
- 2009-03-06 JP JP2010549915A patent/JP2011513005A/en active Pending
- 2009-03-06 EP EP09716422A patent/EP2262566A1/en not_active Withdrawn
- 2009-03-06 US US12/399,532 patent/US20090226502A1/en not_active Abandoned
- 2009-03-06 EP EP09716409A patent/EP2262565A1/en not_active Withdrawn
- 2009-03-06 WO PCT/US2009/036354 patent/WO2009111712A1/en active Application Filing
- 2009-03-06 EP EP13155418.0A patent/EP2594311A3/en not_active Withdrawn
- 2009-03-06 JP JP2010549914A patent/JP2011513004A/en active Pending
- 2009-03-06 WO PCT/US2009/036349 patent/WO2009111709A2/en active Application Filing
- 2009-03-06 CA CA2716985A patent/CA2716985A1/en not_active Abandoned
- 2009-03-06 US US12/399,548 patent/US8114049B2/en not_active Expired - Fee Related
- 2009-03-06 US US12/399,386 patent/US20090227948A1/en not_active Abandoned
- 2009-03-06 EP EP09717854A patent/EP2262547B1/en not_active Not-in-force
-
2011
- 2011-07-08 US US13/179,054 patent/US20110270226A1/en not_active Abandoned
- 2011-11-04 US US13/289,490 patent/US20120053517A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6010480A (en) * | 1993-08-23 | 2000-01-04 | Boston Scientific Corporation | Balloon catheter |
US5707385A (en) * | 1994-11-16 | 1998-01-13 | Advanced Cardiovascular Systems, Inc. | Drug loaded elastic membrane and method for delivery |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150190253A1 (en) * | 2007-11-05 | 2015-07-09 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Coated devices and methods of making coated devices that reduce smooth muscle cell proliferation and platelet activity |
US9415193B2 (en) | 2011-03-04 | 2016-08-16 | W. L. Gore & Associates, Inc. | Eluting medical devices |
US20140371673A1 (en) * | 2012-01-24 | 2014-12-18 | Qualimed Innovative Medizinprodukte Gmbh | Balloon catheter |
US10173038B2 (en) | 2012-09-05 | 2019-01-08 | W. L. Gore & Associates, Inc. | Retractable sheath devices, systems, and methods |
US9901715B2 (en) | 2012-09-05 | 2018-02-27 | W. L. Gore Associates, Inc. | Retractable sheath devices, systems, and methods |
CN104436421A (en) * | 2014-11-28 | 2015-03-25 | 刘宗军 | Medicine injectable balloon |
US20180353733A1 (en) * | 2015-06-12 | 2018-12-13 | Arravasc Limited | Delivery system for a drug coated angioplasty balloon |
US10835721B2 (en) * | 2015-06-12 | 2020-11-17 | Merit Medical Ireland Limited | Delivery system for a drug coated angioplasty balloon |
US11123528B2 (en) | 2016-07-04 | 2021-09-21 | Kaneka Corporation | Balloon catheter and method for manufacturing same |
US11338115B2 (en) | 2016-09-30 | 2022-05-24 | Merit Medical Ireland Limited | Finned angioplasty balloon |
US10668255B2 (en) | 2018-01-19 | 2020-06-02 | Medtronic Vascular, Inc. | Sheath for medically expandable balloon |
US10682492B2 (en) | 2018-01-19 | 2020-06-16 | Medtronic Vascular, Inc. | Expandable balloon sheath |
US10688287B2 (en) | 2018-01-19 | 2020-06-23 | Medtronic, Inc. | Sheath including sheath body and sheath insert |
US10702673B2 (en) | 2018-01-19 | 2020-07-07 | Medtronic Vascular, Inc. | Expandable balloon sheaths |
US10737071B2 (en) | 2018-01-19 | 2020-08-11 | Medtronic, Inc. | Splittable sheath |
Also Published As
Publication number | Publication date |
---|---|
WO2009111716A1 (en) | 2009-09-11 |
JP2011513005A (en) | 2011-04-28 |
WO2009111712A1 (en) | 2009-09-11 |
EP2262565A1 (en) | 2010-12-22 |
US20090227948A1 (en) | 2009-09-10 |
WO2009111709A2 (en) | 2009-09-11 |
US20090226502A1 (en) | 2009-09-10 |
JP2011513004A (en) | 2011-04-28 |
US8114049B2 (en) | 2012-02-14 |
CA2716985A1 (en) | 2009-09-11 |
EP2594311A3 (en) | 2013-07-10 |
EP2594311A2 (en) | 2013-05-22 |
EP2262566A1 (en) | 2010-12-22 |
WO2009111709A3 (en) | 2010-07-08 |
EP2262547B1 (en) | 2013-01-09 |
US20120053517A1 (en) | 2012-03-01 |
US20090227949A1 (en) | 2009-09-10 |
EP2262547A2 (en) | 2010-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110270226A1 (en) | Balloon catheter devices with sheath covering | |
EP2682155B1 (en) | Drug eluting balloons with ability for double treatment | |
US7364585B2 (en) | Medical devices comprising drug-loaded capsules for localized drug delivery | |
US20110087191A1 (en) | Balloon catheter with shape memory sheath for delivery of therapeutic agent | |
EP2793969B1 (en) | Decalcifying heart valve | |
EP1460971B1 (en) | Non-compliant balloon with compliant top-layer to protect coated stents during expansion | |
EP1991285B1 (en) | Balloon catheter having nanotubes | |
EP1848371B1 (en) | Method of incorporating a drug-eluting external body in a medical appliance and a self-expanding stent including a drug-eluting external body | |
US7938799B2 (en) | Medical device for vessel compatibility during high pressure infusion | |
EP1986727B1 (en) | Catheter with porous Balloon | |
US20100069837A1 (en) | Balloon Assembly and Method for Therapeutic Agent Delivery | |
US20070184085A1 (en) | Ultrasound activated medical device | |
US20060195059A1 (en) | Delivery of therapeutic through multiple delivery members | |
WO2007097867A1 (en) | Extendable rolled delivery system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHEN, JOHN;RIZQ, RAED;HARRISON, KENT;AND OTHERS;SIGNING DATES FROM 20090310 TO 20090421;REEL/FRAME:026582/0555 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |